Vyant Bio (VYNT) 10-K 28 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Mar. 17, 2014	Jun. 28, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'CGIX	'	'
Entity Registrant Name	'CANCER GENETICS, INC	'	'
Entity Central Index Key	'0001349929	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	9,275,586	'
Entity Public Float	'	'	$25.30

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS	'	'
Cash and cash equivalents	$49,459,564	$819,906
Accounts receivable, net of allowance for doubtful accounts of 2013 $36,000; 2012 $36,000	1,567,039	850,545
Other current assets	864,616	489,278
Total current assets	51,891,219	2,159,729
FIXED ASSETS, net of accumulated depreciation	1,264,624	964,923
OTHER ASSETS	'	'
Security deposits	1,564	1,564
Restricted cash	300,000	250,000
Loan guarantee and financing fees, net of accumulated amortization of 2013 $517,500; 2012 $929,498	310,500	1,907,502
Patents	401,709	324,764
Investment in joint venture	987,657	'
Deferred offering costs	'	3,343,289
Total other assets	2,001,430	5,827,119
Total Assets	55,157,273	8,951,771
CURRENT LIABILITIES	'	'
Accounts payable and accrued expenses	2,346,240	4,578,761
Obligations under capital leases, current portion	51,400	17,158
Deferred revenue	199,560	468,010
Notes payable, Current Portion	22,298	3,836,567
Line of credit	6,000,000	2,871,200
Total current liabilities	8,619,498	11,771,696
Obligations under capital leases	309,777	7,490
Deferred rent payable	170,789	164,298
Notes payable, Long-Term	'	2,440,683
Line of credit	'	6,000,000
Warrant liability	594,000	12,549,000
Total liabilities	9,694,064	32,933,167
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Common stock, authorized 100,000,000 and 24,000,000 shares, respectively, $0.0001 par value, 9,275,384 and 1,349,936 shares issued and outstanding as of December 31, 2013 and 2012, respectively	927	135
Additional paid-in capital	106,786,862	24,970,255
Treasury stock	'	-17,442
Accumulated deficit	-61,324,580	-48,934,585
Total Stockholders' Equity (Deficit)	45,463,209	-23,981,396
Total Liabilities and Stockholders' Equity (Deficit)	55,157,273	8,951,771
Series A Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Preferred Stock, value	'	59
Series B Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Preferred Stock, value	'	$182

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accounts receivable, allowance for doubtful accounts	$36,000	$36,000
Loan guarantee and financing fees, accumulated amortization	$517,500	$929,498
Preferred stock, shares authorized	9,764,000	'
Common stock, shares authorized	100,000,000	24,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares issued	9,275,384	1,349,936
Common stock, shares outstanding	9,275,384	1,349,936
Series A Preferred Stock [Member]	'	'
Preferred stock, shares authorized	588,000	588,000
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares issued	587,691	587,691
Preferred stock, shares outstanding	'	587,691
Series B Preferred Stock [Member]	'	'
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares issued	1,821,600	1,821,600
Preferred stock, shares outstanding	'	1,821,600

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Revenue	$6,609,957	$4,301,563	$3,019,407
Cost of revenues	4,924,626	3,928,993	3,117,411
Gross profit (loss)	1,685,331	372,570	-98,004
Operating expenses:	'	'	'
Research and development	2,190,204	2,111,947	2,073,661
General and administrative	6,115,035	4,502,424	4,439,170
Sales and marketing	1,841,675	1,398,786	1,574,088
Total operating expenses	10,146,914	8,013,157	8,086,919
Loss from operations	-8,461,583	-7,640,587	-8,184,923
Other income (expense):	'	'	'
Interest expense	-2,387,733	-4,701,028	-1,314,234
Interest income	29,693	'	117
Change in fair value of warrant liability	4,633,000	7,538,000	-10,388,000
Loss on debt and warrant restructuring	'	-1,862,012	'
Debt conversion costs	-6,849,830	'	'
Total other income (expense)	-4,574,870	974,960	-11,702,117
Loss before income taxes	-13,036,453	-6,665,627	-19,887,040
Income tax (benefit) provision	-663,900	'	'
Net loss	($12,372,553)	($6,665,627)	($19,887,040)
Basic net loss per share	($2.65)	($4.97)	($15.61)
Diluted net loss per share	($3.64)	($10.55)	($15.61)
Basic Weighted Average Shares Outstanding	4,665,316	1,342,174	1,274,153
Diluted Weighted Average Shares Outstanding	4,675,974	1,346,161	1,274,153

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (USD $)	Total	Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]
		Series A Preferred Stock [Member]	Series B Preferred Stock [Member]
Balance at Dec. 31, 2010	($6,736,433)	$59	$182	$127	($15,662,559)	($17,442)	($22,381,918)
Balance (in shares) at Dec. 31, 2010	'	587,691	1,821,600	1,271,480	'	'	'
Stock based compensation-employees	306,307	'	'	'	306,307	'	'
Stock based compensation-non-employees	636,810	'	'	'	636,810	'	'
Exercise of warrants	49,999	'	'	1	49,998	'	'
Exercise of warrants (in shares)	'	'	'	3,546	'	'	'
Warrant liability reclassified to equity	6,415,000	'	'	'	6,415,000	'	'
Issuance of common stock	150,000	'	'	2	149,998	'	'
Issuance of common stock (in shares)	'	'	'	20,000	'	'	'
Net loss	-19,887,040	'	'	'	'	'	-19,887,040
Balance at Dec. 31, 2011	-19,065,357	59	182	130	23,220,672	-17,442	-42,268,958
Balance (in shares) at Dec. 31, 2011	'	587,691	1,821,600	1,295,026	'	'	'
Stock based compensation-employees	341,996	'	'	'	341,996	'	'
Stock based compensation-non-employees	573,365	'	'	'	573,365	'	'
Warrant extension	144,000	'	'	'	144,000	'	'
Exercise of warrants	690,227	'	'	5	690,222	'	'
Exercise of warrants (in shares)	'	'	'	54,910	'	'	'
Net loss	-6,665,627	'	'	'	'	'	-6,665,627
Balance at Dec. 31, 2012	-23,981,396	59	182	135	24,970,255	-17,442	-48,934,585
Balance (in shares) at Dec. 31, 2012	'	587,691	1,821,600	1,349,936	'	'	'
Stock based compensation-employees	646,983	'	'	'	646,983	'	'
Stock based compensation-employees (in shares)	'	'	'	2,500	'	'	'
Stock based compensation-non-employees	88,162	'	'	'	88,162	'	'
Vesting of common pursuant to joint venture agreement	231,396	'	'	'	231,396	'	'
Exercise of warrants	612,000	'	'	8	611,992	'	'
Conversion of preferred stock into common stock	'	-59	-182	129	112	'	'
Exercise of warrants (in shares)	'	'	'	78,329	'	'	'
Conversion of preferred stock into common stock (in shares)	'	-587,691	-1,821,600	1,287,325	'	'	'
Conversion of debt into common stock	12,596,066	'	'	96	12,595,970	'	'
Conversion of debt into common stock (in shares)	'	'	'	963,430	'	'	'
Issuance of common stock in IPO, net of offering costs	3,742,643	'	'	69	3,742,574	'	'
Issuance of common stock in IPO, net of offering costs (in shares)	'	'	'	690,000	'	'	'
Issuance of common stock	14,230,372	'	'	160	14,230,212	'	'
Issuance of common stock (in shares)	'	'	'	1,605,000	'	'	'
Issuance of common stock in Follow-On Offering, net of offering costs	42,302,596	'	'	329	42,302,267	'	'
Issuance of common stock in Follow-On Offering, net of offering costs (in shares)	'	'	'	3,286,700	'	'	'
Issuance of common stock pursuant to license agreement	20,000	'	'	'	20,000	'	'
Issuance of common stock pursuant to license agreement (in shares)	'	'	'	2,000	'	'	'
Issuance of common stock pursuant to joint venture agreement	175,300	'	'	1	175,299	'	'
Issuance of common stock pursuant to Joint venture agreement (in shares)	'	'	'	10,000	'	'	'
Reclassification of derivative warrants	7,170,000	'	'	'	7,170,000	'	'
Exercise of options	1,640	'	'	'	1,640	'	'
Exercise of options (in shares)	164	'	'	164	'	'	'
Retirement of treasury stock	'	'	'	'	'	17,442	-17,442
Net loss	-12,372,553	'	'	'	'	'	-12,372,553
Balance at Dec. 31, 2013	$45,463,209	$0	$0	$927	$106,786,862	'	($61,324,580)
Balance (in shares) at Dec. 31, 2013	'	0	0	9,275,384	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'
Net loss	($12,372,553)	($6,665,627)	($19,887,040)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation	311,247	338,176	356,603
Amortization	15,229	15,229	13,048
Provision (recovery) for bad debts	'	-4,597	372,680
Equity-based consulting and compensation expenses	646,983	915,361	1,093,117
Extension of warrants	'	144,000	'
Equity-based research and development/general and administrative expenses	514,858	'	69,000
Change in fair value of warrant liability	-4,633,000	-7,538,000	10,388,000
Amortization of loan guarantee and financing fees	1,194,960	1,427,296	575,285
Accretion of discount on debt	584,692	2,212,154	480,620
Loss on debt and warrant restructuring	'	1,862,012	'
Loss on conversion of debt to equity	6,849,830	'	'
Deferred initial public offering costs expensed	617,706	'	'
Deferred rent	6,491	7,987	25,922
Loss in equity-method investment	12,343	'	'
Change in working capital components:	'	'	'
Accounts receivable	-716,494	-156,968	-355,816
Other current assets	-375,338	-220,009	551,738
Accounts payable, accrued expenses and deferred revenue	-731,471	85,134	1,243,594
Net cash (used in) operating activities	-8,074,517	-7,577,852	-5,073,249
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchase of fixed assets	-257,261	-162,463	-268,632
Patent costs	-92,174	-135,306	-82,872
Investment in joint venture	-1,000,000	'	'
(Increase) decrease in restricted cash	-50,000	-50,000	238,400
Net cash (used in) investing activities	-1,399,435	-347,769	-113,104
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'
Principal payments on capital lease obligations	-17,158	-36,120	-42,708
Proceeds from public offerings of common stock, net of offering costs	61,516,994	'	'
Payment of equity issuance costs	'	-1,373,000	-182,933
Proceeds from option exercises	1,640	'	'
Proceeds from warrant exercises	192,000	635,227	49,999
Proceeds from borrowings on notes payable	'	7,120,000	3,000,000
Proceeds from borrowings on line of credit	'	'	3,200,000
Payments on line of credit	'	'	-200,000
Principal payments on notes payable	-3,579,866	-17,836	'
Net cash provided by financing activities	58,113,610	6,328,271	5,824,358
Net increase (decrease) in cash and cash equivalents	48,639,658	-1,597,350	638,005
CASH AND CASH EQUIVALENTS	'	'	'
Beginning	819,906	2,417,256	1,779,251
Ending	49,459,564	819,906	2,417,256
SUPPLEMENTAL CASH FLOW DISCLOSURE	'	'	'
Cash paid for interest	608,084	1,091,377	253,996
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES	'	'	'
Fixed assets acquired through capital lease arrangement	353,687	'	49,600
Warrants issued with debt	'	6,122,000	1,970,000
Warrants issued for debt guarantee fee	'	1,583,000	831,000
Warrants issued for financing fees	47,000	1,003,000	'
Retirement of treasury stock	17,442	'	'
Conversion of notes payable and lines of credit to common stock	9,634,300	'	'
Conversion of preferred stock to common stock	241	'	'
Reclassification of derivative warrants	7,170,000	'	'
Cashless exercise of derivative warrants	420,000	'	'
Warrant liability reclassified to equity	'	'	6,415,000
Offering costs discounted	733,250	'	'
Accrued IPO costs	'	1,732,016	1,428,340
Accrued expenses recorded as financing fees	'	251,000	'
Accrued expenses recorded as a discount on debt	'	128,800	161,000
Accrued expenses reclassified as derivative warrant liability	221,000	148,000	'
Derivative warrant settled with accrued expense	'	$182,500	'

Organization_Description_of_Bu

Organization, Description of Business, Reverse Stock Split and Charter Amendment	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Organization, Description of Business, Reverse Stock Split and Charter Amendment	'
	Note 1. Organization, Description of Business, Reverse Stock Split and Charter Amendment
	We were incorporated in the State of Delaware on April 8, 1999 and have offices and a laboratory located in Rutherford, New Jersey. Our wholly owned subsidiary, Cancer Genetics Italia SRL (“CGI Italia”), manufactures DNA probes. CGI Italia had approximately $398,000 and $329,000 in total assets at December 31, 2013 and 2012, respectively and approximately $212,000, $91,000 and $103,000 in total revenue for the years ended December 31, 2013, 2012 and 2011, respectively.
	We are an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. Our proprietary tests target cancers that are complicated to prognose and for which it is difficult to predict treatment outcomes using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers. We provide our proprietary tests and services along with a comprehensive range of non-proprietary oncology-focused tests and laboratory services, to oncologists and pathologists at hospitals, cancer centers, reference laboratories and physician offices, as well as to biopharmaceutical companies and clinical research organizations for their clinical trials.
	Reverse Stock Splits
	On February 8, 2013, we filed a charter amendment with the Secretary of State for the State of Delaware and effected a 1-for-2 reverse stock split of our common stock. On March 1, 2013, we filed another charter amendment with the Secretary of State for the State of Delaware and effected a 1-for-2.5 reverse stock split of our common stock. All shares and per share information referenced throughout the consolidated financial statements have been retroactively adjusted to reflect both reverse stock splits.
	Public Offerings
	On April 10, 2013, we sold 690,000 shares of common stock at a public offering price of $10.00 per share and completed our initial public offering (“IPO”) with gross proceeds of $6.9 million (net proceeds of $5 million). Upon the closing of the IPO, all shares of our then-outstanding Series A and Series B convertible preferred stock automatically converted into an aggregate of 1,287,325 shares of common stock. Concurrent with the IPO, certain derivative warrants with a fair value of $7.2 million were reclassified into equity due to the lapsing of anti-dilution provisions in the warrants. Also concurrent with the IPO, $9.6 million of debt converted into 963,430 shares of common stock. All references to our Series A convertible preferred stock refer collectively to the Series A and Series A-1 convertible preferred shares.
	On August 19, 2013, we sold 1,500,000 shares of common stock at a public offering price of $10.00 per share resulting in gross proceeds of $15.0 million (net proceeds of $13.3 million). We used $3.5 million of the proceeds to repay certain indebtedness which was due on August 15, 2013 (see Note 6 for further discussion of the Company’s debt). On September 5, 2013, we sold 105,000 additional common shares pursuant to partial exercise of the underwriter’s over-allotment option which resulted in gross proceeds of $1.1 million (net proceeds of $947,000). All references to the sales of common stock mentioned in this paragraph are referred to as the “Secondary Offering.”
	On October 28, 2013, we sold 3,286,700 shares of common stock, (including the underwriter’s overallotment of 428,700 shares), at a public offering price of $14.00 per share resulting in gross proceeds of $46.0 million (net proceeds of $42.3 million). All references to the sales of common stock mentioned in this paragraph are referred to as the “Follow-On Offering.”

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	Note 2. Significant Accounting Policies
	Basis of presentation: We prepare our financial statements on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.
	Segment Reporting: Operating segments are defined as components of an enterprise about which separate discrete information is used by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in one operating segment, which is the business of developing and selling diagnostic tests.
	Liquidity: Our primary sources of liquidity have been funds generated from our debt financings and equity financings. In addition, we have generated funds from the following sources: (i) the grants received in lieu of federal income tax credits under the Qualifying Therapeutic Discovery Project Program; (ii) grants from the National Institutes of Health and (iii) cash collections from our customers.
	Principles of consolidation: The accompanying consolidated financial statements include the accounts of Cancer Genetics, Inc. and our wholly owned subsidiary, Cancer Genetics Italia SRL. All significant intercompany account balances and transactions have been eliminated in consolidation.
	Use of estimates and assumptions: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates made by management include, among others, realization of amounts billed, realization of long-lived assets, realization of intangible assets, accruals for litigation and registration payments and assumptions used to value stock options and warrants. Actual results could differ from those estimates.
	Risks and uncertainties: We operate in an industry that is subject to intense competition, government regulation and rapid technological change. Our operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure.
	Cash and cash equivalents: Highly liquid investments with original maturities of three months or less when purchased are considered to be cash equivalents. Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents. We maintain cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed insured limits. We have not experienced any losses in such accounts and believe we are not exposed to any significant credit risk on our cash and cash equivalents.
	Revenue recognition: Revenue is recognized in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, Revenue Recognition, and ASC 954-605 Health Care Entities, Revenue Recognition which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the customer or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. In determining whether the price is fixed or determinable, we consider payment limits imposed by insurance carriers and Medicare and the amount of revenue recorded takes into account the historical percentage of revenue we have collected for each type of test for each payor category. Periodically, an adjustment is made to revenue to record differences between our anticipated cash receipts from insurance carriers and Medicare and actual receipts from such payors. For the periods presented, such adjustments were not significant. For direct bill customers (including clinical trials customers), revenue is recorded based upon the contractually agreed upon fee schedule. When assessing collectability, we consider whether we have sufficient payment history to reliably estimate a payor’s individual payment patterns. For new tests where there is no evidence of payment history at the time the tests are completed, we only recognize revenues once reimbursement experience can be established. We then recognize revenue equal to the amount of cash received. Sales of probes are recorded on the shipping date. We do not bill customers for shipping and handling fees and do not collect any sales or other taxes.
	Revenues from grants to support product development are recognized when costs and expenses under the terms of the grant have been incurred and payments under the grants become contractually due.
	Accounts receivable: Accounts receivable are carried at original invoice amount less an estimate for contractual adjustments and doubtful receivables, the amounts of which are determined by an analysis of individual accounts. Our policy for assessing the collectability of receivables is dependent upon the major payor source of the underlying revenue. For direct bill clients, an assessment of credit worthiness is performed prior to initial engagement and is reassessed periodically. If deemed necessary, an allowance is established on receivables from direct bill clients. For insurance carriers where there is not an established pattern of collection, revenue is not recorded until cash is received. For receivables where insurance carriers have made payments to patients instead of directing payments to the Company, an allowance is established for a portion of such receivables. After reasonable collection efforts are exhausted, amounts deemed to be uncollectible are written off against the allowance for doubtful accounts. Since the Company only recognizes revenue to the extent it expects to collect such amounts, bad debt expense related to receivables from patient service revenue is recorded in general and administrative expense in the consolidated statement of operations. Recoveries of accounts receivable previously written off are recorded when received.
	Deferred offering costs: Deferred offering costs represent legal, accounting and other direct costs related to our effort to raise capital through a stock offering. Costs related to our offering activities were deferred until the completion of the offerings, at which time they were reclassified to additional paid-in capital as a reduction of the offering proceeds. In connection with our IPO, $617,706 in deferred offering costs was expensed and approximately $2.5 million in deferred offering costs were reclassified to additional paid-in capital. In connection with our Secondary Offering, we incurred $1.8 million in offering costs and underwriting discounts, all of which were reclassified to additional paid-in-capital upon completion of the offering. In connection with our Follow-On Offering, we incurred $3.7 million in offering costs and underwriting discounts, all of which were reclassified to additional paid-in-capital.
	Deferred revenue: Payments received in advance of services rendered are recorded as deferred revenue and are subsequently recognized as revenue in the period in which the services are performed.
	Fixed assets: Fixed assets consist of diagnostic equipment, furniture and fixtures and leasehold improvements. Fixed assets are carried at cost and are depreciated over the estimated useful lives of the assets, which generally range from five to seven years. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the improvements. The straight-line method is used for depreciation and amortization. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation or amortization with any gain or loss recorded to the consolidated statement of operations.
	Fixed assets are reviewed for impairment whenever changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in our estimate of future cash flows to determine recoverability of these assets. If our assumptions about these assets were to change as a result of events or circumstances, we may be required to record an impairment loss.
	Loan guarantee and financing fees: Loan guarantee fees are amortized on a straight-line basis over the term of the guarantee. Financing fees are amortized using the effective interest method over the term of the related debt.
	Warrant liability: We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant. The warrants are described herein as derivative warrants. We account for these derivative warrants as liabilities. These common stock purchase warrants do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the binomial lattice valuation pricing model with the assumptions as follows: The risk-free interest rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve. The expected life of the warrants is based upon the contractual life of the warrants. Volatility is estimated based on an average of the historical volatilities of the common stock of four entities with characteristics similar to those of the Company. Prior to our IPO, the measurement date fair value of the underlying common shares was based upon an external valuation of our shares. (See Notes 12 and 13). Subsequent to the IPO and Secondary Offering, we used the closing price of our shares on the OTC Bulletin Board and the NASDAQ Capital Market, respectively.
	We compute the fair value of the warrant liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the warrant liability is our stock price, which is subject to significant fluctuation and is not under our control. The resulting effect on our net income (loss) is therefore subject to significant fluctuation and will continue to be so until the warrants are exercised, amended or expire. Assuming all other fair value inputs remain constant, we will record non-cash expense when the stock price increases and non-cash income when the stock price decreases.
	Income taxes: Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred income taxes. Deferred income taxes are recognized for temporary differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future. Deferred income taxes are also recognized for net operating loss carryforwards that are available to offset future taxable income and research and development credits.
	Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. We have established a full valuation allowance on our deferred tax assets as of December 31, 2013 and 2012, therefore we have not recognized any tax benefit or expense in the periods presented.
	ASC 740, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from uncertain tax positions may be recognized when it is more-likely-than-not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. See Note 9 for a discussion of uncertain tax positions.
	Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. There is no accrual for interest or penalties on our consolidated balance sheets at December 31, 2013 or 2012, and we have not recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2013, 2012 or 2011.
	Patents: We account for intangible assets under ASC 350-30. Patents consist of legal fees incurred and are recorded at cost and amortized over the useful lives of the assets, using the straight-line method. Certain patents are in the legal application process and therefore are not currently being amortized. We review the carrying value of patents at the end of each reporting period. Based upon our review, there were no intangible asset impairments in 2013, 2012 or 2011. Accumulated amortization of patents as of December 31, 2013 and 2012 was approximately $56,000 and $41,000, respectively. Future amortization expense for legally approved patents is estimated at $26,800 per year through 2018 and approximately $23,600, $17,100, $14,300, $11,600 and $11,600 for 2019, 2020, 2021, 2022 and 2023, respectively.
	Research and development: Research and development costs associated with service and product development include direct costs of payroll, employee benefits, stock-based compensation and supplies and an allocation of indirect costs including rent, utilities, depreciation and repairs and maintenance. All research and development costs are expensed as they are incurred.
	Registration payment arrangements: We account for our obligations under registration payment arrangements in accordance with ASC 825-20, Registration Payment Arrangements. ASC 825-20 requires us to record a liability if we determine a registration payment is probable and if it can reasonably be estimated. As of December 31, 2013 and 2012, we have an accrued liability of $300,000 and $541,000, respectively, related to the issuance of Series B preferred stock and certain notes payable.
	Stock-based compensation: Stock-based compensation is accounted for in accordance with the provisions of ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. See additional information in Note 11.
	All issuances of stock options or other issuances of equity instruments to employees as the consideration for services received by us are accounted for based on the fair value of the equity instrument issued.
	We account for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity Based Payments to Non-Employees. Under ASC 505-50, we determine the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Stock-based compensation awards issued to non-employees are recorded in expense and additional paid-in capital in stockholders’ equity (deficit) over the applicable service periods based on the fair value of the awards or consideration received at the vesting date.
	Fair value of financial instruments: The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their estimated fair values due to the short term maturities of those financial instruments. These financial instruments are considered Level 1 measurement under the fair value hierarchy. The fair values of our notes payable, lines of credit and capital leases approximate carrying value under Level 2 of the fair value hierarchy. The fair value of warrants recorded as derivative liabilities is described in Note 13.
	Joint venture accounted for under the equity method: The Company records its joint venture investment following the equity method of accounting, reflecting its initial investment in the joint venture and its share of the joint venture’s net earnings or losses and distributions. The Company’s share of the joint venture’s net loss was approximately $12,000 in 2013, the first year of the joint venture’s operations and is included in Research and development expense on the Consolidated Statement of Operations. The Company has a net receivable due from the joint venture of approximately $24,000 and $0 in 2013 and 2012, respectively, which is included in other assets in the Consolidated Balance Sheet. See additional information in Note 16.
	Subsequent events: We have evaluated potential subsequent events through the date the financial statements were issued.
	Earnings (loss) per share: Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares assumed to be outstanding during the period of computation. Diluted earnings per share is computed similar to basic earnings per share except that the numerator is adjusted for the change in fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of dilutive potential common shares outstanding during the period using the treasury stock method.
	Basic net loss and diluted net loss per share data were computed as follows:
		2013			2012			2011
	Numerator:
	Net (loss) for basic earnings per share	$	(12,372,553	)	$	(6,665,627	)	$	(19,887,040	)
	Less change in fair value of warrant liability		4,633,000			7,538,000			—
	Net (loss) for diluted earnings per share	$	(17,005,553	)	$	(14,203,627	)	$	(19,887,040	)
	Denominator:
	Weighted-average basic common shares outstanding		4,665,316			1,342,174			1,274,153
	Assumed conversion of dilutive securities:
	Common stock purchase warrants		10,658			3,987			—
	Potentially dilutive common shares		10,658			3,987			—
	Denominator for diluted earnings per share—adjusted weighted-average shares		4,675,974			1,346,161			1,274,153
	Basic net loss per share	$	(2.65	)	$	(4.97	)	$	(15.61	)
	Diluted net loss per share	$	(3.64	)	$	(10.55	)	$	(15.61	)
	The following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded from the calculation:
		2013			2012			2011
	Common stock purchase warrants		1,701,984			1,102,176			888,739
	Stock options		873,542			553,340			559,990
	Restricted shares of common stock		7,500			—			—
	Common shares issuable upon conversion of Series A Preferred Stock		—			352,614			352,614
	Common shares issuable upon conversion of Series B Preferred Stock		—			364,320			364,320
			2,588,026			2,372,450			2,165,663

Revenue_and_Accounts_Receivabl

Revenue and Accounts Receivable	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Revenue and Accounts Receivable	'
	Note 3. Revenue and Accounts Receivable
	Revenue by payor type for each of the years ended December 31 is comprised of the following:
		2013			2012			2011
	Medicare	$	833,892		$	753,248		$	717,661
	Direct bill (including clinical trials)		3,843,010			1,594,509			350,290
	Grants and royalty		296,877			556,940			315,195
	Insurance carrier and all others		1,636,178			1,396,866			1,636,261
		$	6,609,957		$	4,301,563		$	3,019,407
	Accounts receivable by payor type at December 31, 2013 and 2012 consists of the following:
		2013			2012
	Medicare	$	408,856		$	193,024
	Direct bill (including clinical trials)		628,830			339,763
	Insurance carrier and all others		565,353			353,758
	Allowance for doubtful accounts		(36,000	)		(36,000	)
		$	1,567,039		$	850,545
	We have historically derived a significant portion of our revenue from a limited number of test ordering sites. The test ordering sites are largely hospitals, cancer centers, reference laboratories, physician offices and clinical trial clients. Oncologists and pathologists at these sites order the tests on behalf of the needs of their oncology patients or as part of a clinical trial sponsored by a biopharmaceutical company in which the patient is being enrolled. We generally do not have formal, long-term written agreements with such test ordering sites, and, as a result, we may lose these significant test ordering sites at any time.
	The top five test ordering sites during 2013, 2012 and 2011 accounted for 69%, 58% and 63% respectively, of our clinical testing volumes, with 36%, 46% and 29% respectively, of the volume coming from community hospitals. During the year ended December 31, 2013, there was one site which accounted for more than 10% of our revenue: a clinical trial client accounted for approximately 40% of our revenue. During the year ended December 31, 2012, there were three sites which each accounted for approximately 10% or more of our clinical revenue: a clinical trial client accounted for approximately 13%, a university teaching center accounting for approximately 11%, and; a community hospital accounted for approximately 10%. During 2011, there were two sites which accounted for more than 10% of our revenue: a community hospital accounted for approximately 18% and a community oncology practice accounted for approximately 11%.

Other_Current_Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Other Current Assets	'
	Note 4. Other Current Assets
	At December 31, 2013 and 2012, other current assets consisted of the following:
		2013		2012
	Inventory probes	$	198,789	$	233,767
	Prepaid expenses		593,950		255,511
	Grants receivable		71,877		—
		$	864,616	$	489,278

Lease_Commitments

Lease Commitments	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Lease Commitments	'
	Note 5. Lease Commitments
	We lease our laboratory and research facilities and administrative office space in Rutherford, New Jersey under an escalating lease agreement that expires in February 2018. The lease requires monthly rent for 10 years with periodic rent increases that vary from $1 to $2 per square foot of the rented premises per year. The difference between minimum rent and straight-line rent is recorded as deferred rent payable. The terms of the lease require that a $300,000 security deposit for the facility be held in a stand by letter of credit held in favor of the landlord (see Note 7).
	We acquired office and scientific equipment under long term leases which have been capitalized at the present value of the minimum lease payments. The equipment under these capital leases had a cost of $403,288 and accumulated depreciation of $26,454, as of December 31, 2013.
	Minimum future lease payments under all capital and operating leases as of December 31, 2013 are as follows:
		Capital		Operating		Total
		Leases		Leases
	December 31,
	2014	$	66,709	$	613,121	$	679,830
	2015		59,094		609,828		668,922
	2016		59,094		564,984		624,078
	2017		59,094		564,984		624,078
	2018		59,094		47,082		106,176
	Thereafter		118,190		—		118,190
	Total minimum lease payments		421,275	$	2,399,999	$	2,821,274
	Less amount representing interest		60,098
	Present value of net minimum obligations		361,177
	Less current obligation under capital lease		51,400
	Long-term obligation under capital lease	$	309,777
	Rent expense for the years ended December 31, 2013, 2012 and 2011 was $550,882, $516,173, and $517,667, respectively.
	Subsequent Event
	On January 15, 2014, a capital lease with a future obligation of $7,615 was paid off prior to its contractual due date of May 26, 2014.

Notes_Payable_and_Lines_of_Cre

Notes Payable and Lines of Credit	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Notes Payable and Lines of Credit	'
	Note 6. Notes Payable and Lines of Credit
	Below is a summary of our short-term and long-term debt obligations as of December 31, 2013 and 2012:
		December 31,			December 31,
		2013			2012
	December 2011 Financing Transaction	$	—		$	4,000,000
	Secured Note Payable, short-term		22,298			79,867
	Unamortized debt discount		—			(243,300	)
	Notes Payable, Current Portion	$	22,298		$	3,836,567
	Lines of Credit, Current Portion	$	6,000,000		$	3,000,000
	Unamortized Debt Discount		—			(128,800	)
	Lines of Credit, Current Portion	$	6,000,000		$	2,871,200
	December 2011 Financing Transaction	$	—		$	2,000,000
	2012 Convertible Debt Financing Transaction		—			3,000,000
	December 2012 Bridge Financing Transaction		—			1,000,000
	Other Note Payable		—			100,000
	Secured Note Payable		—			22,298
	Unamortized debt discount		—			(3,681,615	)
	Notes Payable, Long-Term	$	—		$	2,440,683
	Lines of Credit, Long-Term	$	—		$	6,000,000
	Business Line of Credit — Wells Fargo
	At December 31, 2013 and December 31, 2012, we have fully utilized a line of credit with Wells Fargo Bank which provides for maximum borrowings of $6 million. Interest on the line of credit is due monthly equal to 1.75% above the Daily One Month LIBOR rate (2.0% at December 31, 2013). The line of credit requires the repayment of principal, and any unpaid interest, in a single payment due upon maturity. The line of credit matures April 1, 2014, is guaranteed by Mr. Pappajohn, our Chairman of the Board of Directors, and is collateralized by a first lien on all of our assets including the assignment of our approved and pending patent applications.
	Subsequent Event
	In March 2014 we agreed in principle to re-negotiated terms of the line of credit. We anticipate that we will enter into an extension through April 1, 2016 at a rate of interest equal to LIBOR plus 1.75%. Effective April 1, 2014, the pledge of all of our assets and intellectual property as well as the guarantee by Mr. Pappajohn will be released. Under the terms of the extension, we will be required to restrict $6.0 million in cash as collateral. Additionally, will be required to maintain limits on capital spending and are restricted as to the amount we may pledge as collateral for additional borrowings from any source.
	Secured Note Payable
	On September 25, 2012, we entered into a note payable secured by lab equipment due March 25, 2014. The note requires monthly payments of principal and interest at 18% per annum. At December 31, 2013 and 2012, $22,298 and $102,165, respectively, was outstanding under the note.
	Subsequent Event
	On February 21, 2014, a secured note with a future obligation of $22,298 was paid off prior to its contractual due date of March 25, 2014.
	Conversion of Debt concurrent with IPO
	On April 10, 2013, we completed our IPO and converted the following indebtedness into shares of common stock at the IPO price of $10.00 per share:
		Converted Amount			Common Shares
	December 2011 Financing Transaction	$	4,500,000			450,000
	2012 Convertible Debt Financing Transaction		3,000,000			300,000
	December 2012 Bridge Financing Transaction		1,000,000			100,000
	Business Lines of Credit (DAM)		1,000,000			100,000
	Other Note Payable and accrued interest		134,300			13,430
		$	9,634,300			963,430
	In connection with the conversion of debt into common stock, we expensed the applicable remaining debt discounts of $3.5 million, financing fees of $419,000 and a contingently recognizable beneficial conversion feature in the converted debt of $3 million.
	December 2011 Financing Transaction
	At December 31, 2013 and 2012, $0.0 and $6.0 million, respectively, was outstanding under a Credit Agreement dated as of December 21, 2011, as amended and restated as of February 13, 2012.
	The Credit Agreement was with John Pappajohn and Andrew Pecora (indirectly through an investment company), both members of our board of directors, and NNJCA Capital, LLC (“NNJCA”), a limited liability company of which Dr. Pecora is a member. Mr. Pappajohn originally provided $4.0 million of financing, NNJCA originally provided $1.5 million of financing and Dr. Pecora provided $500,000 of financing under the Credit Agreement. On April 10, 2013, Mr. Pappajohn converted $4.0 million and NNJCA converted $500,000 into 450,000 shares of our common stock at the IPO price of $10.00 per share concurrent with our IPO. The remaining outstanding balance of $1.5 million was repaid on August 19, 2013 using a portion of the proceeds from our Secondary Offering.
	The loan bore an annual interest rate equal to the prime rate plus 6.25% (9.50% at August 19, 2013). We accrued a fee due to Pecora and NNJCA of $130,000 of which $32,667 was paid upon conversion of the notes and the remaining balance paid on August 19, 2013. The loan was secured by all of our assets, including our intellectual property, subject to prior first and second liens in favor of Wells Fargo Bank and DAM Holdings, LLC (“DAM”).
	2012 Convertible Debt Financing Transaction
	On April 10, 2013, the entire $3 million outstanding under a Restated Credit Agreement dated as of August 27, 2012, as amended and restated as of October 17, 2012, ($1,750,000 provided by Mr. Pappajohn and $1,250,000 provided by Mr. Mark Oman) was converted into 300,000 shares of common stock at the IPO price of $10 per share.
	Through April 10, 2013, the loan bore interest at the prime rate plus 6.25% (9.50% at April 10, 2013). In February 2013, because we did not consummate our IPO within 181 days of funding, the lenders received ten-year warrants to purchase an aggregate of 7,059 shares of our common stock (issued in proportion to their respective funding amounts) with an exercise price equal to the lesser of (i) $42.50 per share or (ii) the IPO price per share, which was $10.00. Pursuant to a subsequent agreement, described below, the warrants held by Mr. Pappajohn have an exercise price of $15.00 per share. The warrant exercise price is subject to standard anti-dilution protection in the event of stock splits, stock dividends, stock combinations, reclassifications and the like.
	December 2012 Bridge Financing Transaction
	On April 10, 2013, the entire $1 million outstanding under a credit agreement dated as of December 7, 2012, (all of which was provided by Mr. Pappajohn), was converted into 100,000 shares of common stock at the IPO price of $10.00 per share.
	Through April 10, 2013, the loan bore interest at the prime rate plus 6.25% (9.50% at April 10, 2013). The credit agreement required Mr. Pappajohn to convert the outstanding principal balance into shares of our common stock at a conversion price equal to the lesser of $42.50 or our IPO price and as a result all debt was converted on April 10, 2013 at the IPO price of $10.00 per share. In March 2013, Mr. Pappajohn received ten-year warrants to purchase an aggregate of 2,353 shares of our common stock with an exercise price equal to the lesser of (i) $42.50 per share or (ii) the IPO or merger price per share, because we did not consummate our IPO by March 7, 2013. Mr. Pappajohn subsequently agreed that if our final IPO price was below $15.00, there would be no further adjustment to the price or number of shares covered by the warrants held by him. The warrant exercise price is subject to standard anti-dilution protection in the event of stock splits, stock dividends, stock combinations, reclassifications and the like.
	Business Line of Credit – DAM
	At December 31, 2013 and 2012, $0.0 million and $3 million, respectively, were outstanding under a line of credit agreement with DAM.
	On April 10, 2013, $1 million of indebtedness under this line was converted into 100,000 shares of common stock at the IPO price of $10 per share. The remaining outstanding balance of $2.0 million was repaid on August 19, 2013 using a portion of the proceeds from our Secondary Offering.
	Pursuant to an intercreditor agreement between Mr. Pappajohn and DAM (the “Intercreditor Agreement”), we were required to use the proceeds from our IPO to repay the full amount outstanding under the DAM Loan Agreement before any proceeds can be used to repay any debt outstanding under the Wells Fargo Line of Credit. On February 13, 2013, DAM agreed to convert $1.0 million which had been due April 1, 2013 of outstanding indebtedness into shares of common stock at the IPO price per share. We had accrued a fee due to DAM of $52,500 which was paid upon conversion of the line of credit. On March 19, 2013, the maturity date for $2 million of the DAM debt was extended to mature on August 15, 2013. The DAM debt bore an annual interest rate of 10% payable in equal monthly installments.
	Other Note Payable
	At December 31, 2012, notes payable included a $100,000 note payable to Dr. Chaganti, our Chairman of the Board. Accrued interest at December 31, 2012 was approximately $34,300. The note bore interest at 8.5% per annum. On April 10, 2013, the note and accrued interest converted into 13,430 shares of common stock at the IPO price of $10.00 per share.
	Loss on Debt and Warrant Restructuring
	As noted above, we entered into a Restated Credit Agreement with Mr. Pappajohn and Mr. Oman in October 2012 to provide for additional borrowing of $1,000,000 and to remove the conversion price adjustment of a 20% discount to the IPO or merger price if the IPO or merger price is less than $53.12 per share. We evaluated the application of ASC 470-50, Modifications and Extinguishments and ASC 470-60, Troubled Debt Restructurings by Debtors and concluded that the revised terms constituted a debt extinguishment, rather than a debt modification or troubled debt restructuring.
	Also as noted above, we cancelled certain warrants with an exercise price adjustment of a 20% discount to the IPO or merger price if the IPO or merger price is less than $53.13 per share and issued warrants without an exercise price adjustment to a 20% discount to the IPO or merger price if the IPO or merger price is less than $53.13 per share as compensation. In connection with these transactions, we recognized a loss on debt and warrant restructuring during 2012 as presented below:
	Restated 2012 convertible debt financing transaction	$	1,506,512
	Amend warrants granted for guarantee of business line of credit		268,000
	Amend warrants granted for 2011 convertible debt financing transaction		545,000
	Settle warrants granted for guarantee of business line of credit		(129,500	)
	Settle warrants granted for 2011 convertible debt financing transaction		(328,000	)
	Loss on debt and warrant restructuring	$	1,862,012

Letter_of_Credit

Letter of Credit	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Letter of Credit	'
	Note 7. Letter of Credit
	During 2013 we restricted an additional $50,000 in cash and secured a $300,000 letter of credit in favor of our landlord pursuant to the terms of the lease for our Rutherford facility. At December 31, 2013 the letter of credit was fully secured by the restricted cash disclosed on our Consolidated Balance Sheet.

Fixed_Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Fixed Assets	'
	Note 8. Fixed Assets
	Fixed assets are summarized by major classifications as follows:
		2013			2012
	Equipment	$	2,513,066		$	1,914,215
	Furniture and fixtures		461,119			461,119
	Leasehold improvements		595,689			583,592
			3,569,874			2,958,926
	Less accumulated depreciation		(2,305,250	)		(1,994,003	)
	Net fixed assets	$	1,264,624		$	964,923

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Note 9. Income Taxes
	The provision for income taxes for the years ended December 31, 2013, 2012 and 2011 differs from the approximate amount of income tax benefit determined by applying the U.S. federal income tax rate to pre-tax loss, due to the following:
		For the Year Ended						For the Year Ended						For the Year Ended
		December 31, 2013						December 31, 2012						December 31, 2011
		Amount			% of			Amount			% of			Amount			% of
					Pretax						Pretax						Pretax
					Loss						Loss						Loss
	Income tax benefit at federal statutory rate	$	(4,563,000	)		35	%	$	(2,333,000	)		35	%	$	(6,960,000	)		35	%
	State tax provision, net of federal tax benefit		(359,000	)		2.8	%		(661,000	)		9.5	%		604,000	)		3	%
	Tax credits		(126,000	)		1	%		(82,000	)		1.1	%		(57,000	)		0.3	%
	Stock based compensation permanent differences		229,000			-1.8	%		85,000			-1.2	%		43,000			-0.2	%
	Derivative warrant permanent differences		(1,622,000	)		12.4	%		(1,926,000	)		26	%		3,636,000			-18.2	%
	Debt and warrant conversion costs permanent difference		4,118,000			-31.6	%
	State tax benefit of State of New Jersey NOL		(664,000	)		5.1	%		—			—			—			—
	Change in valuation allowance		2,356,000			-18.1	%		4,858,000			-70.2	%		5,320,000			-26.8	%
	Change in uncertain tax positions		—			0	%		—			0	%		(1,395,000	)		7	%
	Other		(33,000	)		0.3	%		59,000			-0.2	%		17,000			-0.1	%
	Provision for income taxes	$	(664,000	)		5.1	%	$	—			0	%	$	—			0	%
	Approximate deferred taxes consist of the following components as of December 31, 2013 and 2012:
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards	$	17,140,000		$	15,134,000
	Accruals and reserves		509,000			486,000
	Non-qualified stock options		877,000			844,000
	Research and development tax credits		603,000			477,000
	Derivative warrant liability		26,000			26,000
	Investment in joint venture		163,000			—
	Other		5,000			7,000
	Total deferred tax assets		19,323,000			16,974,000
	Less valuation allowance		(19,303,000	)		(16,947,000	)
	Net deferred tax assets		20,000			27,000
	Deferred tax liabilities
	Fixed assets		(20,000	)		(27,000	)
	Net deferred taxes	$	—		$	—
	Due to a history of losses we have generated since inception, we believe it is more-likely-than-not that all of the deferred tax assets will not be realized as of December 31, 2013 and 2012. Therefore, we have recorded a full valuation allowance on our deferred tax assets. We have net operating loss carryforwards for federal income tax purposes of approximately $44,000,000 as of December 31, 2013. The net operating loss carryforwards will begin to expire in 2027. Utilization of these carryforwards is subject to limitation due to ownership changes that may delay the utilization of a portion of the carryforwards.
	On January 22, 2013, we executed a sale of $8,018,107 of gross State of New Jersey NOL carryforwards, resulting in the receipt of $663,900. The proceeds were recorded as an income tax benefit for the year ended December 31, 2013. The Company transferred the NOL carryforwards through the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.
	At December 31, 2013 and 2012 we had no uncertain tax positions.
	Subsequent Event
	The Company received approval from the State of New Jersey to sell $22,301,643 of gross state NOL carryforwards and executed a sale in January, 2014 of carryforwards relating to tax years 2009 through 2012, resulting in the receipt of $1,813,941. The Company transferred the NOL carryforwards through the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority. The proceeds were recorded as an income tax benefit in January, 2014.

Capital_Stock

Capital Stock	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Capital Stock	'
	Note 10. Capital Stock
	IPO
	On April 10, 2013, we completed our IPO in which we issued and sold 690,000 shares of common stock (including the underwriter’s overallotment of 90,000 shares) at a public offering price of $10.00 per share resulting in gross proceeds of $6.9 million. In connection with the offering, all outstanding shares of Series A preferred stock were converted into 376,525 shares of common stock, and all outstanding shares of Series B preferred stock were converted into 910,800 shares of common stock. Concurrent with the IPO, we issued 2,000 shares of common stock to Cleveland Clinic pursuant to our license agreement with Cleveland Clinic.
	Secondary Offering
	On August 19, 2013, we sold 1,500,000 shares of common stock at a public offering price of $10.00 per share resulting in gross proceeds of $15.0 million ($13.3 million of net proceeds after offering expenses and underwriting discounts).
	On September 5, 2013, we sold 105,000 additional common shares pursuant to the underwriter’s partial exercise of the over-allotment option which resulted in gross proceeds of $1.1 million ($947,000 of net proceeds after offering expenses and underwriting discounts).
	Follow-On Offering
	On October 28, 2013, we sold 3,286,700 shares of common stock, (including the underwriter’s overallotment of 428,700 shares), at a public offering price of $14.00 per share resulting in gross proceeds of $46.0 million (net proceeds of $42.3 million).
	Preferred Stock
	We are currently authorized to issue up to 9,764,000 shares of preferred stock.

Stock_Option_Plans

Stock Option Plans	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock Option Plans	'
	Note 11. Stock Option Plans
	We have two equity incentive plans: the 2008 Stock Option Plan (the “2008 Plan”) and the 2011 Equity Incentive Plan (the “2011 Plan”, and together with the 2008 Plan, the “Stock Option Plans”). The 2011 Plan was approved by the Board of Directors on June 30, 2011 and was subsequently ratified by stockholders. The 2011 Plan originally authorized the issuance of up to 150,000 shares of common stock under several types of equity awards including stock options, stock appreciation rights, restricted stock awards and other awards defined in the 2011 Plan. On October 12, 2012, the Board of Directors voted to amend the 2011 Plan. The amendment increases the number of shares available for grant under the 2011 Plan from 150,000 to 350,000 shares. This amendment has been ratified by our stockholders.
	The Board of Directors adopted the 2008 Plan on April 29, 2008 and reserved 251,475 shares of common stock for issuance under the plan. On April 1, 2010, the stockholders voted to increase the number of shares reserved by the plan to 550,000. The 2008 Plan is meant to provide additional incentive to officers, employees and consultants to remain in our employment. We are authorized to issue incentive stock options or non-statutory stock options to eligible participants. Options granted are generally exercisable for up to 10 years.
	At December 31, 2013, no shares remain available for future awards under the 2008 Plan and 28,594 shares remain available for future awards under the 2011 Plan.
	As of December 31, 2013, no stock appreciation rights and 7,500 shares of restricted stock had been awarded under the Stock Option Plans.
	We have also issued 48,000 options outside of the Stock Option Plans.
	During 2011, 35,650 options were amended to increase the exercise price from $4.00 to $4.80 based upon a retrospective valuation of our common stock as of the date of grant. The options did not result in the recognition of incremental compensation cost.
	Prior to our IPO in April 2013, the Board of Directors authorized an offer to certain employee and non-employee options holders on the following terms: those holding stock options with a strike price of $25.00 or more had the opportunity to exchange their options for 60% of the number of options currently held with an exercise price equal to the IPO price, which was $10.00 per share, and those holding stock options with a strike price of $12.50 had the opportunity to exchange their options for 80% of the number of options currently held with an exercise price equal to the IPO price which was $10.00 per share. On April 5, 2013, our initial public offering became effective and 336,300 options with exercise prices ranging from $12.50 to $33.80 were exchanged for 242,070 options with an exercise price of $10.00. The options did not result in the recognition of incremental compensation cost. In addition, 53,500 options which were approved to be issued and priced at the IPO price were issued to employees with an exercise price of $10.00 per share.
	Additionally, subject to the adoption of a new equity plan or amendment to increase the shares available for issuance under the 2011 Plan, 50,000 shares of restricted stock have been approved to be issued to the Company’s Chief Executive Officer. Recognition of compensation expense related to these shares of restricted stock will begin at the date of the new plan adoption or amendment of the 2011 Plan, which is when the employee will begin to benefit from, or be adversely affected by, changes in the Company’s stock price.
	A summary of employee and nonemployee stock option activity for the years ended December 31, 2013, 2012 and 2011 is as follows:
			Options Outstanding						Weighted-			Aggregate
									Average			Intrinsic
									Remaining			Value
									Contractual
			Number of			Weighted-			Term (in years)
			Shares			Average
						Exercise
						Price
	Outstanding January 1, 2011			511,660		$	10.9			8.97		$	1,693,760
	Granted			67,615			26.73
	Cancelled or expired			(19,285	)		11.78
	Outstanding December 31, 2011			559,990		$	12.85			8.1		$	11,737,710
	Granted			2,400			33.8
	Cancelled or expired			(9,050	)		23.43
	Outstanding December 31, 2012			553,340		$	12.76			7.13		$	1,142,432
	Granted			426,762			14.57
	Exercised			(164	)		10
	Cancelled or expired			(106,396	)		20.46
	Outstanding December 31, 2013			873,542		$	10.83			7.75		$	3,138,539
	Exercisable, December 31, 2013			413,103		$	7.21			6.08		$	2,726,095
	Aggregate intrinsic value represents the difference between the fair value of our common stock and the exercise price of outstanding, in-the-money options. The fair value of our common stock was $13.78 as of December 31, 2013 and the estimated fair value of our common stock was $9.60 and $33.80 as of December 31, 2012 and 2011, respectively. During the year ended December 31, 2013, we received $1,640 from the exercise of options. The options exercised in 2013 had a total intrinsic value of $1,630. Options were not exercised in 2012 or 2011.
	As of December 31, 2013, total unrecognized compensation cost related to nonvested stock options granted to employees was $4,176,050, which we expect to recognize over the next 3.92 years.
	As of December 31, 2013 and 2012, total unrecognized compensation cost related to nonvested stock options granted to non-employees was $94,359 and $190,500, respectively, which we expect to recognize over the next 1.78 and 0.50 years, respectively. The estimate of unrecognized nonemployee compensation is based on the fair value of the nonvested options as of December 31, 2013 and 2012.
	The following table summarizes information about outstanding and vested stock options granted to employees and non-employees as of December 31, 2013 as follows:
			Options Outstanding									Options Vested and Exercisable
	Exercise Price		Number of			Weighted-			Weighted-			Number of		Weighted-
			Shares			Average			Average			Shares		Average
			Outstanding			Remaining			Exercise					Exercise Price
						Contractual			Price
						Life (in years)
	4			175,000			5.33		$	4			175,000	$	4
	4.8			33,340			6.05			4.8			26,936		4.8
	10			291,990			6.81			10			204,380		10
	11.75			5,600			9.29			11.75			—		11.75
	12.5			200			6.94			12.5			120		12.5
	12.55			10,000			9.95			12.55			—		12.55
	13.81			3,000			9.9			13.81			—		13.81
	14.18			5,500			9.88			14.18			—		14.18
	15.39			348,912			9.77			15.39			6,667		15.39
	Total			873,542			7.75		$	10.83			413,103	$	7.21
	The fair value of options granted to employees is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock-based compensation expense requires us to make assumptions and judgments about the variables used in the calculation, including the fair value of our common stock (see Note 13), the expected term (the period of time that the options granted are expected to be outstanding), the volatility of our common stock, a risk-free interest rate, and expected dividends. We also estimate forfeitures of unvested stock options. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period estimates are revised. No compensation cost is recorded for options that do not vest. We use the simplified calculation of expected life described in the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment, and volatility is based on an average of the historical volatilities of the common stock of four entities with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. We use an expected dividend yield of zero, as we do not anticipate paying any dividends in the foreseeable future. Expected forfeitures are assumed to be zero due to the small number of plan participants and the plan design which has monthly vesting after an initial cliff vesting period.
	The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented:
			Year Ended December 31,
			2013			2012			2011
	Volatility			76.6	%		77.39	%		76.13	%
	Risk free interest rate			1.79	%		1.43	%		2.67	%
	Dividend yield			—			—			—
	Term (years)			6.14			6.5			6.44
	Weighted-average fair value of options granted during the period		$	9.85		$	23.35		$	10.6
	In 2010, we issued an aggregate of 80,000 options to non-employees with an exercise price of $25.00. As described above, on April 5, 2013, these options were exchanged for 48,000 options with an exercise price of $10.00. In October 2013, we issued 10,000 options to a non-employee with an exercise price of $15.39. The following table presents the weighted-average assumptions used to estimate the fair value of options reaching their measurement date for non-employees during the periods presented:
			Year Ended December 31,
			2013			2012			2011
	Volatility			75.68	%		75.01	%		75.45	%
Risk free interest rate			1.53	%		1.26	%		2.85	%
Dividend yield			—			—			—
Term (years)			7.68			8.28			9.23
In October 2013, we issued 2,500 shares of fully vested restricted stock to Mr. Thompson with a grant date fair value of $15.39 per share. In December 2013, we issued 5,000 shares of restricted stock to an employee with a grant date fair value of $12.55 per share. At December 31, 2013, 7,500 restricted shares were outstanding and 2,500 were vested. Also, at December 31, 2013 there was $61,913 of unrecognized compensation cost related to unvested restricted stock which we expect to recognize over 3.04 years.
The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and nonemployees on our Statement of Operations during the periods presented:
		Year Ended December 31,
		2013			2012			2011
Cost of revenues		$	41,470		$	11,753		$	9,603
Research and development			114,189			460,321			423,950
General and administrative			516,127			297,175			263,693
Sales and marketing			63,359			146,112			245,871
Total stock-based compensation		$	735,145		$	915,361		$	943,117
On October 10, 2013 (the “Grant Date”), the Compensation Committee granted each the Company’s Chief Executive Officer and Vice President Research and Development an option to purchase 200,000 shares and 10,000 shares, respectively, of the Company’s common stock at an exercise price of $15.39 per share (the closing price of a share of common stock on The NASDAQ Capital Market on the business day immediately prior to the Grant Date). The options are scheduled to expire on the tenth anniversary of the Grant Date and are scheduled to vest over a period of five years from the Grant Date. The vesting of the option granted to the Chief Executive Officer may be accelerated upon the achievement of certain milestones. In addition, the Company committed to issue 50,000 restricted shares of common stock to the Chief Executive Officer subject to the adoption of a new equity plan or amendment to increase the shares available for issuance under the 2011 Plan.
On October 10, 2013, the Company granted each non-employee director, other than the chairman of the board, options to purchase 10,000 shares of Common Stock at an exercise price of $15.39 (the closing price of a share of common stock on The NASDAQ Capital Market on October 9, 2013), resulting in a total grant of 60,000 options.
On October 10, 2013, the Company granted its incoming chairman of the audit committee, options to purchase 12,312 shares of Common Stock at an exercise price of $15.39 and the Company granted its outgoing chairman of the audit committee 2,500 fully vested shares of restricted stock in recognition of his past service as chairman of the audit committee.
On October 10, 2013, the Company’s board of directors adopted a compensation policy for its non-employee directors, other than the chairman of the board who is compensated pursuant to the terms of a separate consulting agreement. This policy provides for the following cash compensation to the Company’s non-employee directors, other than the chairman of the board:
	•		each non-employee director will receive an annual base fee of $10,000; and
	•		in addition to the $10,000 annual base fee, the chairman of the audit committee will receive an annual fee of $10,000.
This policy provides for the following equity compensation to the Company’s non-employee directors, other than our chairman of the board:
	•		each non-employee director, other than the chairman of the board, will receive bi-annual restricted stock awards of 5,000 shares of common stock; and
	•		each non-employee director, other than the chairman of the board, will receive annual option grants to purchase 10,000 shares of common stock.
The restricted stock awards and option grants will each vest in two equal annual installments. Equity grants under the director compensation policy are subject to the adoption of a new equity plan or amendment to increase the shares available for issuance under the 2011 Plan.
All fees under the director compensation policy will be paid on a quarterly basis and no per meeting fees will be paid. The Company will also reimburse non-employee directors for reasonable expenses incurred in connection with attending board and committee meetings.
Subsequent Events
On January 3, 2014, the board of directors appointed John Pappajohn to serve as the Chairman of the Board, a position previously held by Dr. Raju S.K. Chaganti, effective January 6, 2014. As compensation for serving as the Chairman of the Board, the Company will pay Mr. Pappajohn $100,000 per year and will grant to Mr. Pappajohn, subject to the approval by the Company’s stockholders of a new equity incentive plan or the amendment of the Company’s existing equity incentive plan, 25,000 restricted shares of the Company’s common stock, and options to purchase an aggregate of 100,000 shares of the Company’s common stock. The options will have a term of ten years from the date on which they are granted. The restricted stock and the options will each vest in two equal installments on the one year anniversary and the two year anniversary of the date on which Mr. Pappajohn becomes the Chairman of the Board.
In February, 2014, the Company received $2,020 from a former employee who exercised options to purchase 202 shares of common stock at $10.00 per share.
In February, 2014, the Company modified the vesting terms of 10,000 stock options issued to a former board member, resulting in stock-based compensation expense of $83,000 and which will be reflected in General and administrative expense in the Company’s 10-Q for the quarterly period ended March 31, 2014.
In February, 2014, pursuant to the terms of his renewed consulting agreement, Dr. Chaganti will receive, subject to the adoption of a new equity plan or amendment to increase the shares available for issuance under the 2011 Equity Plan, an option to purchase 200,000 shares of our common stock at a purchase price of $15.89 per share.
In March 2013, the Company announced the appointment of a new Chief Financial Officer effective April 1, 2014. The Company will grant, subject to the adoption of a new equity plan or amendment to increase the shares available for issuance under the 2011 Equity Plan, an option to purchase 90,000 shares of our common stock and 10,000 shares of restricted stock.
In March 2013, the Company accelerated the vesting terms of the stock options previously issued to its outgoing Chief Financial Officer, resulting in stock-based compensation expense of approximately $124,000 and which will be reflected in General and administrative expense in the Company’s 10-Q for the quarterly period ended March 31, 2014.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Warrants	'
	Note 12. Warrants
	We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant. The warrants are described herein as derivative warrants. For all derivative warrants, in the event equity instruments are issued at a price lower than the exercise price of the warrant, the exercise price is adjusted to the price of the new equity instruments issued (price adjustment feature). For certain of these warrants, the number of shares underlying the warrant is also adjusted to an amount computed by dividing the proceeds of the warrant under its original terms by the revised exercise price (share adjustment feature). These warrants are initially recorded as a warrant liability at fair value with a corresponding entry to the loan guarantee fee asset, debt discount, additional paid-in capital or expense dependent upon the service provided in exchange for the warrant grant. Subsequently, any change in fair value is recognized in earnings until such time as the warrants are exercised, amended or expire.
	In connection with debt guarantees and extensions, we issued 1,051,506 warrants to Mr. Pappajohn, a member of our Board of Directors and stockholder, at various dates (see Note 17). These warrants are initially recorded at fair value as a loan guarantee fee amortized over the period of the guarantee to interest expense. The aggregate issue date fair value of the debt guarantee warrants was $1,555,000 in 2012, and $831,000 in 2011. There were no debt guarantee warrants issued in 2013.
	In connection with the acquisition of a line of credit, we issued 60,000 warrants to DAM in March 2011 with an initial estimated fair value of $1,019,000. In March 2012 in exchange for an extension of that line, we issued 15,000 warrants with an initial estimated fair value of $306,000. See Note 6.
	We issued 200 warrants to a consultant for services provided in February and March 2011 and 4,000 warrants to a member of our Board of Directors in connection with the March 2011 line of credit agreement with DAM. These warrants were recorded as consulting expense at an initial estimated fair value of $69,000 and expire in March 2016.
	On September 30, 2011, certain holders of derivative warrants to purchase 228,288 shares of common stock with an exercise price of $4.00 agreed to an amendment to their warrants to remove the exercise price adjustment feature. As of September 30, 2011, the fair value of these warrants of $6,415,000 was reclassified from the warrant liability to equity.
	In connection with the December 2011 Financing Transaction we granted a total of 112,940 warrants at various dates to Mr. Pappajohn, Dr. Pecora and NNJCA. The aggregate issue date fair value of these financing fee warrants was $1,522,000 in 2012 and $951,000 in 2011. In October 2012, 37,646 of these warrants were surrendered in exchange for an increase to the prepayment penalty, and 75,294 were amended in exchange for 20,669 additional warrants with an initial estimated fair value of $606,000. Also in October 2012, Mr. Pappajohn agreed to extend a portion of the debt’s maturity date and in exchange we issued 9,412 additional warrants with an initial estimated fair value of $267,000. See Note 6.
	In connection with the 2012 Convertible Debt Financing Transaction, we granted a total of 28,235 warrants to Mr. Pappajohn and Mr. Oman with an initial estimated fair value of $1,107,000. In October 2012, these warrants were surrendered in exchange for additional financing and 114,510 new warrants with an initial estimated fair value of $4,090,000. See Note 6.
	On September 6, 2012, we extended the maturity date of warrants to purchase 70,598 shares of our common stock which were due to expire on September 10, 2012 to September 28, 2012. On September 27, 2012, we extended the maturity date of 65,328 of these warrants to September 10, 2013. In exchange, the warrants became subject to a lock-up agreement for 180 days after the consummation of an IPO on the same terms as other lock-up agreements in favor of the underwriters of an offering. We determined the fair value of the warrant extensions to be approximately $144,000, which was recorded as general and administrative expense.
	On October 22, 2012, in exchange for amending warrants issued in connection with his guarantee of the Wells Fargo debt, we issued warrants to purchase 10,157 shares of our common stock to Mr. Pappajohn with an exercise price equal to the lesser of (i) $42.50 per share and (ii) the IPO or merger price per share. These warrants were recorded as a financing fee expense at an estimated fair value of $298,000.
	In connection with the December 2012 Bridge Financing transaction, we granted 23,529 warrants to Mr. Pappajohn with an initial estimated fair value of $837,000. See Note 6.
	During 2012, warrants to purchase 54,910 shares were exercised and $690,227 was received and recorded as increases to common stock and additional paid-in capital. An additional 15,164 warrants expired unexercised.
	In connection with the 2012 Convertible Debt Financing Transaction, we granted 4,118 warrants to Mr. Pappajohn and 2,941 warrants to Mr. Oman on February 22, 2013. The warrants have a ten-year term and an exercise price equal to the IPO price of $10.00 per share. Pursuant to a subsequent agreement, the warrants held by Mr. Pappajohn have an exercise price of $15.00 per share. These warrants were initially recorded at fair value as a financing fee asset and were amortized over the period of the note to interest expense. The issue date fair value of these warrants was $221,000.
	In connection with the December 2012 Bridge Financing Transaction, we granted 2,353 ten-year warrants with an exercise price equal to the IPO price of $10.00 per share to Mr. Pappajohn on March 7, 2013. Mr. Pappajohn subsequently agreed that if our final IPO price was below $15.00, there would be no further adjustment to the price or number of shares covered by the warrants held by him. These warrants were initially recorded at fair value as a financing fee asset and were amortized over the period of the note to interest expense. The issue date fair value of these warrants was $47,000.
	On February 11, 2013, John Pappajohn agreed to limit certain anti-dilution rights in his warrants to purchase shares of the Company’s common stock. Subject to the consummation of an IPO prior to April 13, 2013, Mr. Pappajohn agreed that if the final IPO price was below $15.00, the exercise price of the warrants held by him would adjust to $15.00 and the number of shares underlying the warrants would be adjusted as if the IPO price were $15.00 and then there would be no further adjustment to the price or number of shares covered by warrants held by him. In February 2013, certain warrant holders agreed to waive the price and share adjustment provisions of their warrants, except for the anti-dilution provisions related to stock splits, subdivisions and combinations, with respect to an aggregate of 114,030 shares of common stock underlying such warrants, effective immediately following the consummation of our IPO on April 10, 2013 at $10.00 per share.
	On April 10, 2013, the Company completed the IPO at $10.00 per share. The shares of common stock issuable upon the exercise of warrants increased by 838,889 shares and the exercise prices of 1,656,860 warrants were adjusted as a result of share and exercise price adjustment features in certain warrants.
	On April 29, 2013, the Company received $96,000 from shareholders who exercised warrants to purchase 24,000 shares of common stock at $4.00 per share.
	On July 6, 2013, a warrant holder exercised a warrant to purchase 6,000 shares of common stock at an exercise price of $4.00 per share using the net issuance exercise method whereby 2,072 shares were surrendered as payment in full of the exercise price resulting in a net issuance of 3,928 shares.
	On July 8, 2013, the Company received $96,000 from shareholders who exercised warrants to purchase 24,000 shares of common stock at $4.00 per share.
	On September 10, 2013 and September 27, 2013, the Company extended the expiration date of 42,468 warrants for 17 days and 11 days respectively.
	On September 30, 2013, warrant holders exercised warrants to purchase 30,034 shares of common stock at an exercise price of $10.00 per share using the net issuance exercise method whereby 14,313 shares were surrendered as payment in full of the exercise price resulting in a net issuance of 15,721 shares.
	On October 7, 2013 and October 8, 2013, warrant holders exercised warrants to purchase 33,868 shares of common stock, at exercise prices ranging from $10.00 – $14.10 per share, using the net issuance exercise method whereby 23,188 shares were surrendered as payment in full of the exercise price resulting in a net issuance of 10,680 shares.
	Subsequent Events
	In January, 2013, the Company received $950 from a warrant holder who exercised warrants to purchase 95 shares of common stock at $10.00 per share.
	The following table summarizes the warrant activity for the years ending December 31, 2013, 2012 and 2011:
	Issued With / For		Exercise		Warrants		2011		2011			2011			Warrants		2012		2012			2012			2012			Warrants		2013		2013			2013						Warrants
			Price		Outstanding		Warrants		Warrants			Warrants			Outstanding		Warrants		Warrants			Warrants			Warrants			Outstanding		Warrants		Warrants			Warrants			IPO			Outstanding
					January 1,		Issued		Exercised			Amended			December 31,		Issued		Exercised			Surrendered			Expired			December 31,		Issued		Exercised			Expired			Adjustments			December 31,
					2011										2011													2012										(E)			2013
	Non-Derivative Warrants:
	Financing		$	10		—		—		—			—			—		—		—			—			—			—		—		—			—			243,334			243,334
	Financing			14.1		12,411		—		(3,546	)		—			8,865		—		(2,482	)		—			(6,383	)		—		—		—			—			—			—
	Financing			15		—		—		—			—			—		—		—			—			—			—		—		—			—			436,079			436,079
	Debt Guarantee			4		—		—		—			228,288			228,288		—		—			—			—			228,288		—		(54,000	)		—			—			174,288
	Debt Guarantee			10		—		—		—			—			—		—		—			—			—			—		—		—			—			237,500			237,500
	Debt Guarantee			15		—		—		—			—			—		—		—			—			—			—		—		—			—			585,645			585,645
	Series A Pref. Stock			10.75		30,000		—		—			—			30,000		—		(30,000	)		—			—			—		—		—			—			—			—
	Series A Pref. Stock			14.1		89,214		—		—			—			89,214		—		(18,616	)		—			(5,269	)		65,329		—		(29,868	)		(35,461	)		—			—
	Consulting			10		—		—		—			—			—		—		—			—			—			—		—		—			—			29,138			29,138
				12.38F		131,625		—		(3,546	)		228,288			356,367		—		(51,098	)		—			(11,652	)		293,617		—		(83,868	)		(35,461	)		1,531,696			1,705,984
	Derivative Warrants:
	Series A Pref. Stock			4.00 A		7,325		—		—			—			7,325		—		(3,812	)		—			(3,513	)		—		—		—			—			—			—
	Financing			10.00B		—		—		—			—			—		—		—			—			—			—		—		—			—			60,000			60,000
	Financing			25.00 B		—		60,000		—			—			60,000		—		—			—			—			60,000		—		—			—			(60,000	)		—
	Financing			42.50 BCD		—		42,353		—			—			42,353		189,117		—			(156,176	)		—			75,294		—		—			—			(75,294	)		—
	Financing			42.50 AD		—		—		—			—			—		54,314		—			—			—			54,314		2,941		—			—			(57,255	)		—
	Financing			42.50 ACD		—		—		—			—			—		120,865		—			—			—			120,865		6,471		—			—			(127,336	)		—
	Debt Guarantee			10.00A		—		—		—			—			—		—		—			—			—			—		—		—			—			12,500			12,500
	Debt Guarantee			25.00 A		228,288		—		—			(228,288	)		—		—		—			—			—			—		—		—			—			—			—
	Debt Guarantee			25.00 ACD		212,000		—		—			—			212,000		—		—			—			—			212,000		—		—			—			(212,000	)		—
	Debt Guarantee			25.00 AD		100,000		—		—			—			100,000		—		—			—			—			100,000		—		—			—			(100,000	)		—
	Debt Guarantee			32.45 AC		—		40,000		—			—			40,000		—		—			—			—			40,000		—		—			—			(40,000	)		—
	Debt Guarantee			42.50 ACD		—		—		—			—			—		75,392		—			(37,000	)		—			38,392		—		—			—			(38,392	)		—
	Debt Guarantee			42.50 BCD		—		—		—			—			—		37,000		—			—			—			37,000		—		—			—			(37,000	)		—
	Series B Pref. Stock			10.00B		—		—		—			—			—		—		—			—			—			—		—		(34,034	)		—			52,464			18,430
	Series B Pref. Stock			25.00 B		52,464		—		—			—			52,464		—		—			—			—			52,464		—		—			—			(52,464	)		—
	Consulting			10.00B		—		—		—			—			—		—		—			—			—			—		—		—			—			200			200
	Consulting			12.50A D		4,030		—		—			—			4,030		—		—			—			—			4,030		—		—			—			(4,030	)		—
	Consulting			14.10A D		10,000		—		—			—			10,000		—		—			—			—			10,000		—		—			—			(10,000	)		—
	Consulting			25.00B D		—		200		—			—			200		—		—			—			—			200		—		—			—			(200	)		—
	Consulting			25.00AD		—		4,000		—			—			4,000		—		—			—			—			4,000		—		—			—			(4,000	)		—
				10.00F		614,107		146,553		—			(228,288	)		532,372		476,688		(3,812	)		(193,176	)		(3,513	)		808,559		9,412		(34,034	)		—			(692,807	)		91,130
			$	12.26F		745,732		146,553		(3,546	)		—			888,739		476,688		(54,910	)		(193,176	)		(15,165	)		1,102,176		9,412		(117,902	)		(35,461	)		838,889			1,797,114
A	These warrants are subject to fair value accounting and contain exercise price and number of share adjustment features. See Note 13.
B	These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note 13.
C	On February 11, 2013, these warrants held by John Pappajohn were amended to limit the adjustment feature(s) to $15.00 per share in an initial public offering (totaling 530,022 warrants).
D	The exercise price and/or number of share adjustment features of these warrants expired and are no longer subject to fair value accounting after our initial public offering.
E	On April 10, 2013 the Company completed the IPO at $10.00 per share. The shares of common stock issuable upon the exercise of warrants outstanding as of April 10, 2013 increased by 838,889 shares and the exercise prices of 1,656,860 warrants were adjusted as a result of the share and exercise price adjustment features described above.
F	Weighted average exercise prices are as of December 31, 2013.

Fair_Value_of_Warrants

Fair Value of Warrants	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value of Warrants	'
	Note 13. Fair Value of Warrants
	The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at the date of issue during the years ended December 31, 2013, 2012 and 2011 and at December 31, 2013, April 5, 2013 (IPO valuation date) and December 31, 2012. In computing the fair value of the warrants, if the stated exercise price of the warrants exceeded the assumed value of the Company stock at the date the fair value was being computed, the exercise price and number of shares (if applicable) underlying the warrants were adjusted to reflect an assumed trigger of the price and/or share adjustment features related to the applicable warrants. Such adjustments were only applicable to 2012 and 2013 due to the relative price of the warrants and the assumed Company stock price:
		Issued During						As of						IPO Date
		the Year Ended						December 31,						April 5,
		December 31,
		2012			2011			2013			2012			2013
	Debt Guarantee
	Exercise Price	$	9.6		$	32.45		$	10		$	28.78		$	13.56
	Expected life (years)		4.66			5			0.83			2.66			2.42
	Expected volatility		80.05	%		77.35	%		57.33	%		67.71	%		66.37	%
	Risk-free interest rate		0.82	%		1.76	%		0.13	%		0.37	%		0.32	%
	Expected dividend yield		0	%		0	%		0	%		0	%		0	%
		As of December 31,
		2013			2012
	Series B
	Exercise Price	$	10		$	9.6
	Expected life (years)		1.92			2.92
	Expected volatility		59.26	%		61.44	%
	Risk-free interest rate		0.38	%		0.36	%
	Expected dividend yield		0	%		0	%
		As of December 31,						IPO Date
		2013			2012			April 5, 2013
	Consulting
	Exercise Price	$	10		$	9.6		$	10
	Expected life (years)		2.14			2.48			2.33
	Expected volatility		62.63	%		63.29	%		63.2	%
	Risk-free interest rate		0.38	%		0.28	%		0.27	%
	Expected dividend yield		0	%		0	%		0	%
		Issued During						As of December 31,						IPO Date
		the Year Ended												April 5,
		December 31,
		2013			2012			2013			2012			2013
	Financing
	Exercise Price	$	13.34		$	23.69		$	10		$	9.6		$	13.21
	Expected life (years)		9.78			6.81			2.25			6.66			8.3
	Expected volatility		74.7	%		77.74	%		64.4	%		73.38	%		73.22	%
	Risk-free interest rate		1.95	%		1.19	%		0.38	%		1.06	%		1.44	%
	Expected dividend yield		0	%		0	%		0	%		0	%		0	%
	The assumed ranges of Company stock prices used in computing the warrant fair value for warrants issued during the year is as follows: in 2013, $9.60—$20.26; in 2012, $9.60—$33.80; in 2011, $ 11.90—$33.80. In determining the fair value of warrants issued at each reporting date, the assumed Company stock price was $13.78 (the closing price on the NASDAQ Capital Market) at December 31, 2013 and $9.60 (per an external valuation estimate) at December 31, 2012.
	The following table summarizes the derivative warrant activity subject to fair value accounting for the years ended December 31, 2013, 2012 and 2011:
		Issued with			Issued with			Issued For			Issued For			Issued For			Total
		Series A			Series B			Debt			Consulting			Financing
		Preferred			Preferred			Guarantee
		Stock			Stock
	Fair value of warrants outstanding as of December 31, 2010	$	63,000		$	314,000		$	3,793,000		$	100,000		$	—		$	4,270,000
	Fair value of warrants issued		—			—			831,000			69,000			1,970,000			2,870,000
	Warrants amended		—			—			(6,415,000	)		—			—			(6,415,000	)
	Change in fair value of warrants		157,000			846,000			8,784,000			278,000			323,000			10,388,000
	Fair value of warrants outstanding as of December 31, 2011		220,000			1,160,000			6,993,000			447,000			2,293,000			11,113,000
	Fair value of warrants issued		—			—			1,583,000			—			4,961,000			6,544,000
	Fair value of warrants exercised		(55,000	)		—			—			—			—			(55,000	)
	Warrant restructuring		—			—			268,000			—			2,217,000			2,485,000
	Change in fair value of warrants		(165,000	)		(930,000	)		(3,165,000	)		(300,000	)		(2,978,000	)		(7,538,000	)
	Fair value of warrants outstanding as of December 31, 2012		—			230,000			5,679,000			147,000			6,493,000			12,549,000
	Fair value of warrants issued		—			—			—			—			268,000			268,000
	Fair value of warrants exercised		—			(420,000	)		—			—			—			(420,000	)
	Reclassification to equity in IPO		—			—			(2,514,000	)		(108,000	)		(4,548,000	)		(7,170,000	)
	Change in fair value of warrants		—			307,000			(3,101,000	)		(38,000	)		(1,801,000	)		(4,633,000	)
	Fair value of warrants outstanding as of December 31, 2013	$	—		$	117,000		$	64,000		$	1,000		$	412,000		$	594,000

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Note 14. Fair Value Measurements
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Fair Value Measurements and Disclosures Topic of the FASB Accounting Standards Codification requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. Inputs to valuation techniques refer to the assumptions that market participants would use in pricing the asset or liability. Inputs may be observable, meaning those that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from independent sources, or unobservable, meaning those that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. In that regard, the Topic establishes a fair value hierarchy for valuation inputs that give the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.
	The fair value hierarchy is as follows:
	Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that we have the ability to access as of the measurement date.
	Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
	Level 3: Significant unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing an asset or liability.
	The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value:
		2013
		Total		Quoted Prices in		Significant Other		Significant
				Active Markets for		Observable		Unobservable
				Identical Assets		Inputs		Inputs
				(Level 1)		(Level 2)		(Level 3)
	Warrant liability	$	594,000		—		—	$	594,000
		2012
		Total		Quoted Prices in		Significant Other		Significant
				Active Markets for		Observable		Unobservable
				Identical Assets		Inputs		Inputs
				(Level 1)		(Level 2)		(Level 3)
	Warrant liability	$	12,549,000		—		—	$	12,549,000
	The warrant liability consists of stock warrants we issued that contain an exercise price adjustment feature. In accordance with derivative accounting for warrants, we calculated the fair value of warrants and the assumptions used are described in Note 13, “Fair Value of Warrants”. Realized and unrealized gains and losses related to the change in fair value of the warrant liability are included in other income (expense) on the Consolidated Statement of Operations.
	A table summarizing the activity for the derivative warrant liability which is measured at fair value using Level 3 inputs is presented in Note 13.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Contingencies	'
	Note 15. Contingencies
	In the normal course of business, the Company is involved in various claims and legal proceedings. In the opinion of management, the ultimate liability or disposition thereof is not expected to have a material adverse effect on our financial condition, results of operations or liquidity.
	From 2000 to 2004, we operated a clinical laboratory in Milford, Massachusetts providing cancer screening services. The clinical laboratory participated in the Medicare program. The Office of the Inspector General of the U.S. Department of Health and Human Services and the United States Department of Justice informed us in February 2009 that they were contemplating commencing a civil False Claims Act action against us with respect to certain alleged improper billing practices and overpayments relating to operations at the Milford, Massachusetts clinical laboratory. In January 2012, we executed a settlement agreement with the United States Department of Justice. Pursuant to the settlement agreement, we neither admitted liability nor conceded that the claims of the United States are well founded. In January 2012, we paid to the United States the sum of $1,000,000 in connection with the investigation. We received $400,000 in December 2011 from our insurance carrier related to this matter. The net amount shown in our statement of operations is a net recovery of $200,000 in 2011 and an expense of $800,000 in 2010.

Joint_Venture_Agreement

Joint Venture Agreement	12 Months Ended
	Dec. 31, 2013
Equity Method Investments And Joint Ventures [Abstract]	'
Joint Venture Agreement	'
	Note 16. Joint Venture Agreement
	In November 2011, we entered into an affiliation agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), subsequently amended. Under the agreement, we formed a joint venture with Mayo in May 2013 to focus on developing oncology diagnostic services and tests utilizing next generation sequencing. The joint venture is a limited liability company, with each party initially holding fifty percent of the issued and outstanding membership interests of the new entity (the “JV”). The agreement also requires aggregate total capital contributions by us of up to $5.0 million over the next two and a half years. We currently anticipate that we will make capital contributions of $1.0 million in the second quarter of 2014 and $2.0 million each on the first and second anniversaries of the closing date, respectively, with the latter two installments subject to the JV’s achievement of certain operational milestones agreed upon by the board of governors of the JV. In exchange for its membership interests, Mayo’s capital contribution will take the form of cash, staff, services, hardware and software resources, laboratory space and instrumentation, the fair market value of which will be approximately equal to $6 million. Mayo’s continued contribution will also be conditioned upon the JV’s achievement of certain milestones. The operation of the joint venture may also divert management time from operating our business. No assurances can be given that we will be able to fully fund the joint venture agreement, or that, even if funded, the joint venture will ever achieve the research, development and commercial objectives currently contemplated by the parties, such as the discovery and commercialization of new diagnostic tests utilizing next-generation sequencing. If the development efforts of the joint venture do not result in commercially successful tests or services, it will have an adverse effect on our business, financial condition and results of operations.
	In exchange for the membership interests in the JV, we made an initial capital contribution of $1.0 million in October 2013. In addition, in October 2013, we issued 10,000 shares of our common stock to Mayo pursuant to our affiliation agreement with Mayo and recorded an expense of approximately $175,000. We also recorded additional expense of approximately $231,000 during the fourth quarter of 2013 related to shares issued to Mayo in November of 2011 as the JV achieved certain performance milestones. We currently anticipate that we will make an additional capital contribution of $1.0 million in the second quarter of 2014.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Note 17. Related Party Transactions
	John Pappajohn, a member of the Board of Directors and stockholder, personally guarantees our revolving line of credit with Wells Fargo Bank through April 1, 2014. As consideration for his guarantee, as well as each of the eight extensions of this facility through December 31, 2013, Mr. Pappajohn received warrants to purchase an aggregate of 1,051,506 shares of common stock of which Mr. Pappajohn assigned warrants to purchase 284,000 shares of common stock to certain third parties. Warrants to purchase 395,825 shares of common stock have been exercised by Mr. Pappajohn through December 31, 2013. After adjustment pursuant to the terms of the warrants in conjunction with our IPO, the number of these warrants outstanding retained by Mr. Pappajohn was 585,645 at $15.00 per share and 44,288 at $4.00 per share (See Notes 6 and 12).
	In addition, John Pappajohn also had loaned us an aggregate of $6,750,000 (all of which was converted into 675,000 shares of common stock at the IPO price of $10.00 per share). In connection with these loans, Mr. Pappajohn received warrants to purchase an aggregate of 202,630 shares of common stock. After adjustment pursuant to the terms of the warrants in conjunction with our IPO, the number of warrants outstanding was 436,079 at $15.00 per share at December 31, 2013 (See Notes 6 and 12).
	Andrew Pecora (indirectly through an investment company), when a member of our board of directors, and NNJCA, a limited liability company of which Dr. Pecora is a member originally provided $500,000 and $1.5 million of financing, respectively, under a Credit Agreement dated as of December 21, 2011, as amended and restated as of February 13, 2012. On April 10, 2013, NNJCA converted $500,000 of its outstanding indebtedness into 50,000 shares of our common stock at the IPO price of $10.00 per share concurrent with our IPO. On August 19, 2013, the remaining principal under these notes were repaid to Dr. Pecora and NNJCA using a portion of the proceeds from our Secondary Offering. The loan bore an annual interest rate equal to the prime rate plus 6.25% (9.50% at August 19, 2013). We paid a pre-payment penalty due to Pecora and NNJCA of $130,000 of which $32,667 was paid upon conversion of the notes and the remaining balance paid on August 19, 2013.
	On May 19, 2006, we issued a convertible promissory note in favor of our then Chairman and founder, Dr. Chaganti, the holder, which obligated us to pay the holder the sum of $100,000, together with interest at the rate of 8.5% per annum, due April 1, 2014. Interest expense totaled $2,400, $8,400, and $8,400 for the years ended December 31, 2013, 2012, and 2011, respectively (see Note 4 for additional information regarding the conversion of the promissory note into common stock concurrent with our IPO on April 10, 2013). Pursuant to a consulting and advisory agreement, Dr. Chaganti also received options to purchase a total of 36,000 shares of common stock at a price of $10.00 per share which vested over a two year period. Total non-cash stock-based compensation recognized under the consulting agreement for the years ended December 31, 2013, 2012 and 2011 were $76,220, $430,600 and $401,250, respectively. Additionally, on September 15, 2010, we entered into a three-year consulting agreement with Dr. Chaganti which was subsequently renewed through December 31, 2016 pursuant to which Dr. Chaganti receives $5,000 per month for providing consulting and technical support services. Total expenses for each of the years ended December 31, 2013, 2012 and 2011 were $60,000. In addition, Dr. Chaganti received a non-qualified stock option to purchase 60,000 shares of common stock at a purchase price of $25.00 per share vesting quarterly beginning October 1, 2010 and which are fully vested at December 31, 2013. Pursuant to the terms of the renewed consulting agreement, Dr. Chaganti will receive, subject to the adoption of a new equity plan or amendment to increase the shares available for issuance under the 2011 Equity Plan, an option to purchase 200,000 shares of our common stock at a purchase price of $15.89 per share. Also pursuant to the consulting agreement, Dr. Chaganti assigned to us all rights to any inventions which he may invent during the course of rendering consulting services to us. In exchange for this assignment, if the USPTO issues a patent for an invention on which Dr. Chaganti is listed as an inventor, we are required to pay Dr. Chaganti (i) a one-time payment of $50,000 and (ii) 1% of any net revenues we receive from any licensed sales of the invention. As of December 31, 2013, we accrued $150,000 for three patents that were issued where Dr. Chaganti was listed as inventor.
	On July 1, 2010, we entered into a one-year consulting agreement with Edmund Cannon, a member of our board of directors, pursuant to which Mr. Cannon received $2,000 per calendar quarter for providing consulting services to us in connection with our clinical lab business. The agreement was terminated in 2011. Total expense under the consulting agreement was $4,000 in 2011.
	On August 15, 2010, we entered into a two-year consulting agreement with Dr. Pecora, then a member of our board of directors, pursuant to which Dr. Pecora received $5,000 per month for providing consulting and advisory services. Dr. Pecora also received stock options under the consulting and advisory agreement to purchase a total of 12,000 shares of common stock at price of $25.00 per share which vested over a two year period. Total expense for 2011 under the consulting agreement was $45,000 paid in cash and $235,560 expensed under the stock option plan. The cash component of this agreement was terminated by mutual consent in August 2011. Total expenses for 2013 and 2012 under the consulting agreement were $0 and $142,740, respectively expensed under the stock option plan.
	In August 2010, we entered into a consulting agreement with Equity Dynamics, Inc., an entity controlled by John Pappajohn, pursuant to which Equity Dynamics, Inc. receives a monthly fee of $10,000 plus reimbursement of expenses. Total expenses for each 2013 and 2012 under the consulting agreement were $120,000 per year. As of December 31, 2013 and December 31, 2012, we owed Equity Dynamics, Inc. $0 and $132,679, respectively.
	We issued 4,000 warrants to Mr. Thompson, a member of our Board of Directors in connection with the March 2011 line of credit agreement with DAM. These warrants were recorded as consulting expense at an initial estimated fair value of $69,000 and expire in March 2016.
	In February 2012, we granted 28,235 warrants proportionately to Pecora and NNJCA upon their funding of $0.5 million and $1.5 million, respectively, under a new Credit Agreement. (See Notes 6 and 12). On May 15, 2012 and on August 14, 2012, we issued 4,706 of these warrants proportionately to Pecora and NNJCA (Notes 6 and 12). On October 15, 2012, Dr. Pecora and NNJCA agreed to surrender warrants to purchase an aggregate of 37,646 shares of our common stock issued in connection with this transaction in exchange for an amendment to increase the pre-payment penalties by $130,000.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of presentation	'
	Basis of presentation: We prepare our financial statements on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.
Segment Reporting	'
	Segment Reporting: Operating segments are defined as components of an enterprise about which separate discrete information is used by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in one operating segment, which is the business of developing and selling diagnostic tests.
Liquidity	'
	Liquidity: Our primary sources of liquidity have been funds generated from our debt financings and equity financings. In addition, we have generated funds from the following sources: (i) the grants received in lieu of federal income tax credits under the Qualifying Therapeutic Discovery Project Program; (ii) grants from the National Institutes of Health and (iii) cash collections from our customers.
Principles of consolidation	'
	Principles of consolidation: The accompanying consolidated financial statements include the accounts of Cancer Genetics, Inc. and our wholly owned subsidiary, Cancer Genetics Italia SRL. All significant intercompany account balances and transactions have been eliminated in consolidation.
Use of estimates and assumptions	'
	Use of estimates and assumptions: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates made by management include, among others, realization of amounts billed, realization of long-lived assets, realization of intangible assets, accruals for litigation and registration payments and assumptions used to value stock options and warrants. Actual results could differ from those estimates.
Risks and uncertainties	'
	Risks and uncertainties: We operate in an industry that is subject to intense competition, government regulation and rapid technological change. Our operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure.
Cash and cash equivalents	'
	Cash and cash equivalents: Highly liquid investments with original maturities of three months or less when purchased are considered to be cash equivalents. Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents. We maintain cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed insured limits. We have not experienced any losses in such accounts and believe we are not exposed to any significant credit risk on our cash and cash equivalents.
Revenue recognition	'
	Revenue recognition: Revenue is recognized in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, Revenue Recognition, and ASC 954-605 Health Care Entities, Revenue Recognition which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the customer or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. In determining whether the price is fixed or determinable, we consider payment limits imposed by insurance carriers and Medicare and the amount of revenue recorded takes into account the historical percentage of revenue we have collected for each type of test for each payor category. Periodically, an adjustment is made to revenue to record differences between our anticipated cash receipts from insurance carriers and Medicare and actual receipts from such payors. For the periods presented, such adjustments were not significant. For direct bill customers (including clinical trials customers), revenue is recorded based upon the contractually agreed upon fee schedule. When assessing collectability, we consider whether we have sufficient payment history to reliably estimate a payor’s individual payment patterns. For new tests where there is no evidence of payment history at the time the tests are completed, we only recognize revenues once reimbursement experience can be established. We then recognize revenue equal to the amount of cash received. Sales of probes are recorded on the shipping date. We do not bill customers for shipping and handling fees and do not collect any sales or other taxes.
	Revenues from grants to support product development are recognized when costs and expenses under the terms of the grant have been incurred and payments under the grants become contractually due.
Accounts receivable	'
	Accounts receivable: Accounts receivable are carried at original invoice amount less an estimate for contractual adjustments and doubtful receivables, the amounts of which are determined by an analysis of individual accounts. Our policy for assessing the collectability of receivables is dependent upon the major payor source of the underlying revenue. For direct bill clients, an assessment of credit worthiness is performed prior to initial engagement and is reassessed periodically. If deemed necessary, an allowance is established on receivables from direct bill clients. For insurance carriers where there is not an established pattern of collection, revenue is not recorded until cash is received. For receivables where insurance carriers have made payments to patients instead of directing payments to the Company, an allowance is established for a portion of such receivables. After reasonable collection efforts are exhausted, amounts deemed to be uncollectible are written off against the allowance for doubtful accounts. Since the Company only recognizes revenue to the extent it expects to collect such amounts, bad debt expense related to receivables from patient service revenue is recorded in general and administrative expense in the consolidated statement of operations. Recoveries of accounts receivable previously written off are recorded when received.
Deferred offering costs	'
	Deferred offering costs: Deferred offering costs represent legal, accounting and other direct costs related to our effort to raise capital through a stock offering. Costs related to our offering activities were deferred until the completion of the offerings, at which time they were reclassified to additional paid-in capital as a reduction of the offering proceeds. In connection with our IPO, $617,706 in deferred offering costs was expensed and approximately $2.5 million in deferred offering costs were reclassified to additional paid-in capital. In connection with our Secondary Offering, we incurred $1.8 million in offering costs and underwriting discounts, all of which were reclassified to additional paid-in-capital upon completion of the offering. In connection with our Follow-On Offering, we incurred $3.7 million in offering costs and underwriting discounts, all of which were reclassified to additional paid-in-capital.
Deferred revenue	'
	Deferred revenue: Payments received in advance of services rendered are recorded as deferred revenue and are subsequently recognized as revenue in the period in which the services are performed.
Fixed assets	'
	Fixed assets: Fixed assets consist of diagnostic equipment, furniture and fixtures and leasehold improvements. Fixed assets are carried at cost and are depreciated over the estimated useful lives of the assets, which generally range from five to seven years. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the improvements. The straight-line method is used for depreciation and amortization. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation or amortization with any gain or loss recorded to the consolidated statement of operations.
	Fixed assets are reviewed for impairment whenever changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in our estimate of future cash flows to determine recoverability of these assets. If our assumptions about these assets were to change as a result of events or circumstances, we may be required to record an impairment loss.
Loan guarantee and financing fees	'
	Loan guarantee and financing fees: Loan guarantee fees are amortized on a straight-line basis over the term of the guarantee. Financing fees are amortized using the effective interest method over the term of the related debt.
Warrant liability	'
	Warrant liability: We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant. The warrants are described herein as derivative warrants. We account for these derivative warrants as liabilities. These common stock purchase warrants do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the binomial lattice valuation pricing model with the assumptions as follows: The risk-free interest rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve. The expected life of the warrants is based upon the contractual life of the warrants. Volatility is estimated based on an average of the historical volatilities of the common stock of four entities with characteristics similar to those of the Company. Prior to our IPO, the measurement date fair value of the underlying common shares was based upon an external valuation of our shares. (See Notes 12 and 13). Subsequent to the IPO and Secondary Offering, we used the closing price of our shares on the OTC Bulletin Board and the NASDAQ Capital Market, respectively.
	We compute the fair value of the warrant liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the warrant liability is our stock price, which is subject to significant fluctuation and is not under our control. The resulting effect on our net income (loss) is therefore subject to significant fluctuation and will continue to be so until the warrants are exercised, amended or expire. Assuming all other fair value inputs remain constant, we will record non-cash expense when the stock price increases and non-cash income when the stock price decreases.
Income taxes	'
	Income taxes: Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred income taxes. Deferred income taxes are recognized for temporary differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future. Deferred income taxes are also recognized for net operating loss carryforwards that are available to offset future taxable income and research and development credits.
	Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. We have established a full valuation allowance on our deferred tax assets as of December 31, 2013 and 2012, therefore we have not recognized any tax benefit or expense in the periods presented.
	ASC 740, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from uncertain tax positions may be recognized when it is more-likely-than-not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. See Note 9 for a discussion of uncertain tax positions.
	Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. There is no accrual for interest or penalties on our consolidated balance sheets at December 31, 2013 or 2012, and we have not recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2013, 2012 or 2011.
Patents	'
	Patents: We account for intangible assets under ASC 350-30. Patents consist of legal fees incurred and are recorded at cost and amortized over the useful lives of the assets, using the straight-line method. Certain patents are in the legal application process and therefore are not currently being amortized. We review the carrying value of patents at the end of each reporting period. Based upon our review, there were no intangible asset impairments in 2013, 2012 or 2011. Accumulated amortization of patents as of December 31, 2013 and 2012 was approximately $56,000 and $41,000, respectively. Future amortization expense for legally approved patents is estimated at $26,800 per year through 2018 and approximately $23,600, $17,100, $14,300, $11,600 and $11,600 for 2019, 2020, 2021, 2022 and 2023, respectively.
Research and development	'
	Research and development: Research and development costs associated with service and product development include direct costs of payroll, employee benefits, stock-based compensation and supplies and an allocation of indirect costs including rent, utilities, depreciation and repairs and maintenance. All research and development costs are expensed as they are incurred.
Registration payment arrangements	'
	Registration payment arrangements: We account for our obligations under registration payment arrangements in accordance with ASC 825-20, Registration Payment Arrangements. ASC 825-20 requires us to record a liability if we determine a registration payment is probable and if it can reasonably be estimated. As of December 31, 2013 and 2012, we have an accrued liability of $300,000 and $541,000, respectively, related to the issuance of Series B preferred stock and certain notes payable.
Stock-based compensation	'
	Stock-based compensation: Stock-based compensation is accounted for in accordance with the provisions of ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. See additional information in Note 11.
	All issuances of stock options or other issuances of equity instruments to employees as the consideration for services received by us are accounted for based on the fair value of the equity instrument issued.
	We account for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity Based Payments to Non-Employees. Under ASC 505-50, we determine the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Stock-based compensation awards issued to non-employees are recorded in expense and additional paid-in capital in stockholders’ equity (deficit) over the applicable service periods based on the fair value of the awards or consideration received at the vesting date.
Fair value of financial instruments	'
	Fair value of financial instruments: The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their estimated fair values due to the short term maturities of those financial instruments. These financial instruments are considered Level 1 measurement under the fair value hierarchy. The fair values of our notes payable, lines of credit and capital leases approximate carrying value under Level 2 of the fair value hierarchy. The fair value of warrants recorded as derivative liabilities is described in Note 13.
Joint venture accounted for under the equity method	'
	Joint venture accounted for under the equity method: The Company records its joint venture investment following the equity method of accounting, reflecting its initial investment in the joint venture and its share of the joint venture’s net earnings or losses and distributions. The Company’s share of the joint venture’s net loss was approximately $12,000 in 2013, the first year of the joint venture’s operations and is included in Research and development expense on the Consolidated Statement of Operations. The Company has a net receivable due from the joint venture of approximately $24,000 and $0 in 2013 and 2012, respectively, which is included in other assets in the Consolidated Balance Sheet. See additional information in Note 16.
Subsequent events	'
	Subsequent events: We have evaluated potential subsequent events through the date the financial statements were issued.
Earnings (loss) per share	'
	Earnings (loss) per share: Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares assumed to be outstanding during the period of computation. Diluted earnings per share is computed similar to basic earnings per share except that the numerator is adjusted for the change in fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of dilutive potential common shares outstanding during the period using the treasury stock method.
	Basic net loss and diluted net loss per share data were computed as follows:
		2013			2012			2011
	Numerator:
	Net (loss) for basic earnings per share	$	(12,372,553	)	$	(6,665,627	)	$	(19,887,040	)
	Less change in fair value of warrant liability		4,633,000			7,538,000			—
	Net (loss) for diluted earnings per share	$	(17,005,553	)	$	(14,203,627	)	$	(19,887,040	)
	Denominator:
	Weighted-average basic common shares outstanding		4,665,316			1,342,174			1,274,153
	Assumed conversion of dilutive securities:
	Common stock purchase warrants		10,658			3,987			—
	Potentially dilutive common shares		10,658			3,987			—
	Denominator for diluted earnings per share—adjusted weighted-average shares		4,675,974			1,346,161			1,274,153
	Basic net loss per share	$	(2.65	)	$	(4.97	)	$	(15.61	)
	Diluted net loss per share	$	(3.64	)	$	(10.55	)	$	(15.61	)
	The following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded from the calculation:
		2013			2012			2011
	Common stock purchase warrants		1,701,984			1,102,176			888,739
	Stock options		873,542			553,340			559,990
	Restricted shares of common stock		7,500			—			—
	Common shares issuable upon conversion of Series A Preferred Stock		—			352,614			352,614
	Common shares issuable upon conversion of Series B Preferred Stock		—			364,320			364,320
			2,588,026			2,372,450			2,165,663

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Computation of Basic Net Income (Loss) and Diluted Net Loss per Share Data	'
	Basic net loss and diluted net loss per share data were computed as follows:
		2013			2012			2011
	Numerator:
	Net (loss) for basic earnings per share	$	(12,372,553	)	$	(6,665,627	)	$	(19,887,040	)
	Less change in fair value of warrant liability		4,633,000			7,538,000			—
	Net (loss) for diluted earnings per share	$	(17,005,553	)	$	(14,203,627	)	$	(19,887,040	)
	Denominator:
	Weighted-average basic common shares outstanding		4,665,316			1,342,174			1,274,153
	Assumed conversion of dilutive securities:
	Common stock purchase warrants		10,658			3,987			—
	Potentially dilutive common shares		10,658			3,987			—
	Denominator for diluted earnings per share—adjusted weighted-average shares		4,675,974			1,346,161			1,274,153
	Basic net loss per share	$	(2.65	)	$	(4.97	)	$	(15.61	)
	Diluted net loss per share	$	(3.64	)	$	(10.55	)	$	(15.61	)
Summary of Potentially Dilutive Adjustments to Weighted Average Number of Common Shares Excluded from Calculation	'
	The following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded from the calculation:
		2013			2012			2011
	Common stock purchase warrants		1,701,984			1,102,176			888,739
	Stock options		873,542			553,340			559,990
	Restricted shares of common stock		7,500			—			—
	Common shares issuable upon conversion of Series A Preferred Stock		—			352,614			352,614
	Common shares issuable upon conversion of Series B Preferred Stock		—			364,320			364,320
			2,588,026			2,372,450			2,165,663

Revenue_and_Accounts_Receivabl1

Revenue and Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Schedule of Revenue by Payor Type	'
	Revenue by payor type for each of the years ended December 31 is comprised of the following:
		2013			2012			2011
	Medicare	$	833,892		$	753,248		$	717,661
	Direct bill (including clinical trials)		3,843,010			1,594,509			350,290
	Grants and royalty		296,877			556,940			315,195
	Insurance carrier and all others		1,636,178			1,396,866			1,636,261
		$	6,609,957		$	4,301,563		$	3,019,407
Schedule of accounts Receivable by Payor Type	'
	Accounts receivable by payor type at December 31, 2013 and 2012 consists of the following:
		2013			2012
	Medicare	$	408,856		$	193,024
	Direct bill (including clinical trials)		628,830			339,763
	Insurance carrier and all others		565,353			353,758
	Allowance for doubtful accounts		(36,000	)		(36,000	)
		$	1,567,039		$	850,545

Other_Current_Assets_Tables

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Schedule of Other Current Assets	'
	At December 31, 2013 and 2012, other current assets consisted of the following:
		2013		2012
	Inventory probes	$	198,789	$	233,767
	Prepaid expenses		593,950		255,511
	Grants receivable		71,877		—
		$	864,616	$	489,278

Lease_Commitments_Tables

Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Minimum Future Lease Payments Under All Capital and Operating Leases	'
	Minimum future lease payments under all capital and operating leases as of December 31, 2013 are as follows:
		Capital		Operating		Total
		Leases		Leases
	December 31,
	2014	$	66,709	$	613,121	$	679,830
	2015		59,094		609,828		668,922
	2016		59,094		564,984		624,078
	2017		59,094		564,984		624,078
	2018		59,094		47,082		106,176
	Thereafter		118,190		—		118,190
	Total minimum lease payments		421,275	$	2,399,999	$	2,821,274
	Less amount representing interest		60,098
	Present value of net minimum obligations		361,177
	Less current obligation under capital lease		51,400
	Long-term obligation under capital lease	$	309,777

Notes_Payable_and_Lines_of_Cre1

Notes Payable and Lines of Credit (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Summary of Short-Term and Long-Term Debt Obligations	'
	Below is a summary of our short-term and long-term debt obligations as of December 31, 2013 and 2012:
		December 31,			December 31,
		2013			2012
	December 2011 Financing Transaction	$	—		$	4,000,000
	Secured Note Payable, short-term		22,298			79,867
	Unamortized debt discount		—			(243,300	)
	Notes Payable, Current Portion	$	22,298		$	3,836,567
	Lines of Credit, Current Portion	$	6,000,000		$	3,000,000
	Unamortized Debt Discount		—			(128,800	)
	Lines of Credit, Current Portion	$	6,000,000		$	2,871,200
	December 2011 Financing Transaction	$	—		$	2,000,000
	2012 Convertible Debt Financing Transaction		—			3,000,000
	December 2012 Bridge Financing Transaction		—			1,000,000
	Other Note Payable		—			100,000
	Secured Note Payable		—			22,298
	Unamortized debt discount		—			(3,681,615	)
	Notes Payable, Long-Term	$	—		$	2,440,683
	Lines of Credit, Long-Term	$	—		$	6,000,000
Conversion of Indebtedness into Shares of Common Stock	'
	On April 10, 2013, we completed our IPO and converted the following indebtedness into shares of common stock at the IPO price of $10.00 per share:
		Converted Amount			Common Shares
	December 2011 Financing Transaction	$	4,500,000			450,000
	2012 Convertible Debt Financing Transaction		3,000,000			300,000
	December 2012 Bridge Financing Transaction		1,000,000			100,000
	Business Lines of Credit (DAM)		1,000,000			100,000
	Other Note Payable and accrued interest		134,300			13,430
		$	9,634,300			963,430
Loss on Debt and Warrant Restructuring	'
	In connection with these transactions, we recognized a loss on debt and warrant restructuring during 2012 as presented below:
	Restated 2012 convertible debt financing transaction	$	1,506,512
	Amend warrants granted for guarantee of business line of credit		268,000
	Amend warrants granted for 2011 convertible debt financing transaction		545,000
	Settle warrants granted for guarantee of business line of credit		(129,500	)
	Settle warrants granted for 2011 convertible debt financing transaction		(328,000	)
	Loss on debt and warrant restructuring	$	1,862,012

Fixed_Assets_Tables

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Fixed Assets Summary by Major Classifications	'
	Fixed assets are summarized by major classifications as follows:
		2013			2012
	Equipment	$	2,513,066		$	1,914,215
	Furniture and fixtures		461,119			461,119
	Leasehold improvements		595,689			583,592
			3,569,874			2,958,926
	Less accumulated depreciation		(2,305,250	)		(1,994,003	)
	Net fixed assets	$	1,264,624		$	964,923

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Reconciliation	'
	The provision for income taxes for the years ended December 31, 2013, 2012 and 2011 differs from the approximate amount of income tax benefit determined by applying the U.S. federal income tax rate to pre-tax loss, due to the following:
		For the Year Ended						For the Year Ended						For the Year Ended
		December 31, 2013						December 31, 2012						December 31, 2011
		Amount			% of			Amount			% of			Amount			% of
					Pretax						Pretax						Pretax
					Loss						Loss						Loss
	Income tax benefit at federal statutory rate	$	(4,563,000	)		35	%	$	(2,333,000	)		35	%	$	(6,960,000	)		35	%
	State tax provision, net of federal tax benefit		(359,000	)		2.8	%		(661,000	)		9.5	%		604,000	)		3	%
	Tax credits		(126,000	)		1	%		(82,000	)		1.1	%		(57,000	)		0.3	%
	Stock based compensation permanent differences		229,000			-1.8	%		85,000			-1.2	%		43,000			-0.2	%
	Derivative warrant permanent differences		(1,622,000	)		12.4	%		(1,926,000	)		26	%		3,636,000			-18.2	%
	Debt and warrant conversion costs permanent difference		4,118,000			-31.6	%
	State tax benefit of State of New Jersey NOL		(664,000	)		5.1	%		—			—			—			—
	Change in valuation allowance		2,356,000			-18.1	%		4,858,000			-70.2	%		5,320,000			-26.8	%
	Change in uncertain tax positions		—			0	%		—			0	%		(1,395,000	)		7	%
	Other		(33,000	)		0.3	%		59,000			-0.2	%		17,000			-0.1	%
	Provision for income taxes	$	(664,000	)		5.1	%	$	—			0	%	$	—			0	%
Components of Approximate Deferred Tax	'
	Approximate deferred taxes consist of the following components as of December 31, 2013 and 2012:
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards	$	17,140,000		$	15,134,000
	Accruals and reserves		509,000			486,000
	Non-qualified stock options		877,000			844,000
	Research and development tax credits		603,000			477,000
	Derivative warrant liability		26,000			26,000
	Investment in joint venture		163,000			—
	Other		5,000			7,000
	Total deferred tax assets		19,323,000			16,974,000
	Less valuation allowance		(19,303,000	)		(16,947,000	)
	Net deferred tax assets		20,000			27,000
	Deferred tax liabilities
	Fixed assets		(20,000	)		(27,000	)
	Net deferred taxes	$	—		$	—

Stock_Option_Plans_Tables

Stock Option Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Employee and Nonemployee Stock Option Activity	'
	A summary of employee and nonemployee stock option activity for the years ended December 31, 2013, 2012 and 2011 is as follows:
		Options Outstanding						Weighted-			Aggregate
								Average			Intrinsic
								Remaining			Value
								Contractual
		Number of			Weighted-			Term (in years)
		Shares			Average
					Exercise
					Price
	Outstanding January 1, 2011		511,660		$	10.9			8.97		$	1,693,760
	Granted		67,615			26.73
	Cancelled or expired		(19,285	)		11.78
	Outstanding December 31, 2011		559,990		$	12.85			8.1		$	11,737,710
	Granted		2,400			33.8
	Cancelled or expired		(9,050	)		23.43
	Outstanding December 31, 2012		553,340		$	12.76			7.13		$	1,142,432
	Granted		426,762			14.57
	Exercised		(164	)		10
	Cancelled or expired		(106,396	)		20.46
	Outstanding December 31, 2013		873,542		$	10.83			7.75		$	3,138,539
	Exercisable, December 31, 2013		413,103		$	7.21			6.08		$	2,726,095
Summary of Outstanding and Vested Stock Options Granted	'
	The following table summarizes information about outstanding and vested stock options granted to employees and non-employees as of December 31, 2013 as follows:
		Options Outstanding									Options Vested and Exercisable
	Exercise Price	Number of			Weighted-			Weighted-			Number of		Weighted-
		Shares			Average			Average			Shares		Average
		Outstanding			Remaining			Exercise					Exercise Price
					Contractual			Price
					Life (in years)
	4		175,000			5.33		$	4			175,000	$	4
	4.8		33,340			6.05			4.8			26,936		4.8
	10		291,990			6.81			10			204,380		10
	11.75		5,600			9.29			11.75			—		11.75
	12.5		200			6.94			12.5			120		12.5
	12.55		10,000			9.95			12.55			—		12.55
	13.81		3,000			9.9			13.81			—		13.81
	14.18		5,500			9.88			14.18			—		14.18
	15.39		348,912			9.77			15.39			6,667		15.39
	Total		873,542			7.75		$	10.83			413,103	$	7.21
Effects of Stock-Based Compensation Related to Stock Option and Restricted Stock Awards	'
	The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and nonemployees on our Statement of Operations during the periods presented:
		Year Ended December 31,
		2013			2012			2011
	Cost of revenues	$	41,470		$	11,753		$	9,603
	Research and development		114,189			460,321			423,950
	General and administrative		516,127			297,175			263,693
	Sales and marketing		63,359			146,112			245,871
	Total stock-based compensation	$	735,145		$	915,361		$	943,117
Employees [Member]	'
Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted	'
	The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented:
		Year Ended December 31,
		2013			2012			2011
	Volatility		76.6	%		77.39	%		76.13	%
	Risk free interest rate		1.79	%		1.43	%		2.67	%
	Dividend yield		—			—			—
	Term (years)		6.14			6.5			6.44
	Weighted-average fair value of options granted during the period	$	9.85		$	23.35		$	10.6
Non-Employees [Member]	'
Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted	'
	The following table presents the weighted-average assumptions used to estimate the fair value of options reaching their measurement date for non-employees during the periods presented:
		Year Ended December 31,
		2013			2012			2011
	Volatility		75.68	%		75.01	%		75.45	%
	Risk free interest rate		1.53	%		1.26	%		2.85	%
	Dividend yield		—			—			—
	Term (years)		7.68			8.28			9.23

Warrants_Tables

Warrants (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Summary of Warrant Activity	'
	The following table summarizes the warrant activity for the years ending December 31, 2013, 2012 and 2011:
	Issued With / For		Exercise		Warrants		2011		2011			2011			Warrants		2012		2012			2012			2012			Warrants		2013		2013			2013						Warrants
			Price		Outstanding		Warrants		Warrants			Warrants			Outstanding		Warrants		Warrants			Warrants			Warrants			Outstanding		Warrants		Warrants			Warrants			IPO			Outstanding
					January 1,		Issued		Exercised			Amended			December 31,		Issued		Exercised			Surrendered			Expired			December 31,		Issued		Exercised			Expired			Adjustments			December 31,
					2011										2011													2012										(E)			2013
	Non-Derivative Warrants:
	Financing		$	10		—		—		—			—			—		—		—			—			—			—		—		—			—			243,334			243,334
	Financing			14.1		12,411		—		(3,546	)		—			8,865		—		(2,482	)		—			(6,383	)		—		—		—			—			—			—
	Financing			15		—		—		—			—			—		—		—			—			—			—		—		—			—			436,079			436,079
	Debt Guarantee			4		—		—		—			228,288			228,288		—		—			—			—			228,288		—		(54,000	)		—			—			174,288
	Debt Guarantee			10		—		—		—			—			—		—		—			—			—			—		—		—			—			237,500			237,500
	Debt Guarantee			15		—		—		—			—			—		—		—			—			—			—		—		—			—			585,645			585,645
	Series A Pref. Stock			10.75		30,000		—		—			—			30,000		—		(30,000	)		—			—			—		—		—			—			—			—
	Series A Pref. Stock			14.1		89,214		—		—			—			89,214		—		(18,616	)		—			(5,269	)		65,329		—		(29,868	)		(35,461	)		—			—
	Consulting			10		—		—		—			—			—		—		—			—			—			—		—		—			—			29,138			29,138
				12.38F		131,625		—		(3,546	)		228,288			356,367		—		(51,098	)		—			(11,652	)		293,617		—		(83,868	)		(35,461	)		1,531,696			1,705,984
	Derivative Warrants:
	Series A Pref. Stock			4.00 A		7,325		—		—			—			7,325		—		(3,812	)		—			(3,513	)		—		—		—			—			—			—
	Financing			10.00B		—		—		—			—			—		—		—			—			—			—		—		—			—			60,000			60,000
	Financing			25.00 B		—		60,000		—			—			60,000		—		—			—			—			60,000		—		—			—			(60,000	)		—
	Financing			42.50 BCD		—		42,353		—			—			42,353		189,117		—			(156,176	)		—			75,294		—		—			—			(75,294	)		—
	Financing			42.50 AD		—		—		—			—			—		54,314		—			—			—			54,314		2,941		—			—			(57,255	)		—
	Financing			42.50 ACD		—		—		—			—			—		120,865		—			—			—			120,865		6,471		—			—			(127,336	)		—
	Debt Guarantee			10.00A		—		—		—			—			—		—		—			—			—			—		—		—			—			12,500			12,500
	Debt Guarantee			25.00 A		228,288		—		—			(228,288	)		—		—		—			—			—			—		—		—			—			—			—
	Debt Guarantee			25.00 ACD		212,000		—		—			—			212,000		—		—			—			—			212,000		—		—			—			(212,000	)		—
	Debt Guarantee			25.00 AD		100,000		—		—			—			100,000		—		—			—			—			100,000		—		—			—			(100,000	)		—
	Debt Guarantee			32.45 AC		—		40,000		—			—			40,000		—		—			—			—			40,000		—		—			—			(40,000	)		—
	Debt Guarantee			42.50 ACD		—		—		—			—			—		75,392		—			(37,000	)		—			38,392		—		—			—			(38,392	)		—
	Debt Guarantee			42.50 BCD		—		—		—			—			—		37,000		—			—			—			37,000		—		—			—			(37,000	)		—
	Series B Pref. Stock			10.00B		—		—		—			—			—		—		—			—			—			—		—		(34,034	)		—			52,464			18,430
	Series B Pref. Stock			25.00 B		52,464		—		—			—			52,464		—		—			—			—			52,464		—		—			—			(52,464	)		—
	Consulting			10.00B		—		—		—			—			—		—		—			—			—			—		—		—			—			200			200
	Consulting			12.50A D		4,030		—		—			—			4,030		—		—			—			—			4,030		—		—			—			(4,030	)		—
	Consulting			14.10A D		10,000		—		—			—			10,000		—		—			—			—			10,000		—		—			—			(10,000	)		—
	Consulting			25.00B D		—		200		—			—			200		—		—			—			—			200		—		—			—			(200	)		—
	Consulting			25.00AD		—		4,000		—			—			4,000		—		—			—			—			4,000		—		—			—			(4,000	)		—
				10.00F		614,107		146,553		—			(228,288	)		532,372		476,688		(3,812	)		(193,176	)		(3,513	)		808,559		9,412		(34,034	)		—			(692,807	)		91,130
			$	12.26F		745,732		146,553		(3,546	)		—			888,739		476,688		(54,910	)		(193,176	)		(15,165	)		1,102,176		9,412		(117,902	)		(35,461	)		838,889			1,797,114
	A	These warrants are subject to fair value accounting and contain exercise price and number of share adjustment features. See Note 13.
	B	These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note 13.
	C	On February 11, 2013, these warrants held by John Pappajohn were amended to limit the adjustment feature(s) to $15.00 per share in an initial public offering (totaling 530,022 warrants).
	D	The exercise price and/or number of share adjustment features of these warrants expired and are no longer subject to fair value accounting after our initial public offering.
	E	On April 10, 2013 the Company completed the IPO at $10.00 per share. The shares of common stock issuable upon the exercise of warrants outstanding as of April 10, 2013 increased by 838,889 shares and the exercise prices of 1,656,860 warrants were adjusted as a result of the share and exercise price adjustment features described above.
	F	Weighted average exercise prices are as of December 31, 2013.

Fair_Value_of_Warrants_Tables

Fair Value of Warrants (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Assumptions Used in Computing Fair Value of Derivative Warrants	'
	The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at the date of issue during the years ended December 31, 2013, 2012 and 2011 and at December 31, 2013, April 5, 2013 (IPO valuation date) and December 31, 2012. In computing the fair value of the warrants, if the stated exercise price of the warrants exceeded the assumed value of the Company stock at the date the fair value was being computed, the exercise price and number of shares (if applicable) underlying the warrants were adjusted to reflect an assumed trigger of the price and/or share adjustment features related to the applicable warrants. Such adjustments were only applicable to 2012 and 2013 due to the relative price of the warrants and the assumed Company stock price:
		Issued During						As of						IPO Date
		the Year Ended						December 31,						April 5,
		December 31,
		2012			2011			2013			2012			2013
	Debt Guarantee
	Exercise Price	$	9.6		$	32.45		$	10		$	28.78		$	13.56
	Expected life (years)		4.66			5			0.83			2.66			2.42
	Expected volatility		80.05	%		77.35	%		57.33	%		67.71	%		66.37	%
	Risk-free interest rate		0.82	%		1.76	%		0.13	%		0.37	%		0.32	%
	Expected dividend yield		0	%		0	%		0	%		0	%		0	%
		As of December 31,
		2013			2012
	Series B
	Exercise Price	$	10		$	9.6
	Expected life (years)		1.92			2.92
	Expected volatility		59.26	%		61.44	%
	Risk-free interest rate		0.38	%		0.36	%
	Expected dividend yield		0	%		0	%
		As of December 31,						IPO Date
		2013			2012			April 5, 2013
	Consulting
	Exercise Price	$	10		$	9.6		$	10
	Expected life (years)		2.14			2.48			2.33
	Expected volatility		62.63	%		63.29	%		63.2	%
	Risk-free interest rate		0.38	%		0.28	%		0.27	%
	Expected dividend yield		0	%		0	%		0	%
		Issued During						As of December 31,						IPO Date
		the Year Ended												April 5,
		December 31,
		2013			2012			2013			2012			2013
	Financing
	Exercise Price	$	13.34		$	23.69		$	10		$	9.6		$	13.21
	Expected life (years)		9.78			6.81			2.25			6.66			8.3
	Expected volatility		74.7	%		77.74	%		64.4	%		73.38	%		73.22	%
	Risk-free interest rate		1.95	%		1.19	%		0.38	%		1.06	%		1.44	%
	Expected dividend yield		0	%		0	%		0	%		0	%		0	%
Summary of Derivative Warrant Activity	'
	The following table summarizes the derivative warrant activity subject to fair value accounting for the years ended December 31, 2013, 2012 and 2011:
		Issued with			Issued with			Issued For			Issued For			Issued For			Total
		Series A			Series B			Debt			Consulting			Financing
		Preferred			Preferred			Guarantee
		Stock			Stock
	Fair value of warrants outstanding as of December 31, 2010	$	63,000		$	314,000		$	3,793,000		$	100,000		$	—		$	4,270,000
	Fair value of warrants issued		—			—			831,000			69,000			1,970,000			2,870,000
	Warrants amended		—			—			(6,415,000	)		—			—			(6,415,000	)
	Change in fair value of warrants		157,000			846,000			8,784,000			278,000			323,000			10,388,000
	Fair value of warrants outstanding as of December 31, 2011		220,000			1,160,000			6,993,000			447,000			2,293,000			11,113,000
	Fair value of warrants issued		—			—			1,583,000			—			4,961,000			6,544,000
	Fair value of warrants exercised		(55,000	)		—			—			—			—			(55,000	)
	Warrant restructuring		—			—			268,000			—			2,217,000			2,485,000
	Change in fair value of warrants		(165,000	)		(930,000	)		(3,165,000	)		(300,000	)		(2,978,000	)		(7,538,000	)
	Fair value of warrants outstanding as of December 31, 2012		—			230,000			5,679,000			147,000			6,493,000			12,549,000
	Fair value of warrants issued		—			—			—			—			268,000			268,000
	Fair value of warrants exercised		—			(420,000	)		—			—			—			(420,000	)
	Reclassification to equity in IPO		—			—			(2,514,000	)		(108,000	)		(4,548,000	)		(7,170,000	)
	Change in fair value of warrants		—			307,000			(3,101,000	)		(38,000	)		(1,801,000	)		(4,633,000	)
	Fair value of warrants outstanding as of December 31, 2013	$	—		$	117,000		$	64,000		$	1,000		$	412,000		$	594,000

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Summary of Financial Liabilities Measured at Fair Value on Recurring Basis	'
	The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value:
		2013
		Total		Quoted Prices in		Significant Other		Significant
				Active Markets for		Observable		Unobservable
				Identical Assets		Inputs		Inputs
				(Level 1)		(Level 2)		(Level 3)
	Warrant liability	$	594,000		—		—	$	594,000
		2012
		Total		Quoted Prices in		Significant Other		Significant
				Active Markets for		Observable		Unobservable
				Identical Assets		Inputs		Inputs
				(Level 1)		(Level 2)		(Level 3)
	Warrant liability	$	12,549,000		—		—	$	12,549,000

Organization_Description_of_Bu1

Organization, Description of Business, Reverse Stock Split and Charter Amendment - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

Oct. 28, 2013

Apr. 10, 2013

Mar. 01, 2013

Feb. 08, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Apr. 10, 2013

Aug. 19, 2013

Dec. 31, 2013

Sep. 05, 2013

Cancer Genetics Italia SRL [Member]

Cancer Genetics Italia SRL [Member]

Cancer Genetics Italia SRL [Member]

IPO [Member]

Secondary Offering [Member]

Secondary Offering [Member]

Secondary Offering [Member]

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total assets

'

'

'

'

$55,157,273

$8,951,771

'

'

$398,000

$329,000

'

'

'

'

'

Revenue

'

'

'

'

6,609,957

4,301,563

3,019,407

'

212,000

91,000

103,000

'

'

'

'

Reverse stock split ratio

'

'

0.4

0.5

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

3,286,700

690,000

'

'

9,275,384

1,349,936

'

10,000

'

'

'

690,000

1,500,000

'

'

Public offering price per share

$14

$10

'

'

'

'

'

'

'

'

'

$10

$10

'

'

Gross proceeds from public offering

46,000,000

6,900,000

'

'

'

'

'

'

'

'

'

6,900,000

15,000,000

'

'

Net proceeds from initial public offering

42,300,000

'

'

'

61,516,994

'

'

'

'

'

'

5,000,000

'

'

'

Aggregate number of Series A and Series B convertible preferred stock converted into common stock

'

1,287,325

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of derivative warrants

'

7,200,000

'

'

7,170,000

'

'

'

'

'

'

'

'

'

'

Value of debt converted

'

9,634,300

'

'

9,634,300

'

'

'

'

'

'

'

'

'

'

Conversion of debt into common stock

'

963,430

'

'

12,596,066

'

'

'

'

'

'

'

'

'

'

Net proceeds from secondary public offering

'

'

'

'

'

'

'

'

'

'

'

'

13,300,000

'

'

Amount used for repayment of certain indebtedness

'

'

'

'

'

'

'

'

'

'

'

'

'

3,500,000

'

Additional common stock sold at public offering

'

'

'

'

'

'

'

'

'

'

'

'

'

105,000

105,000

Additional gross proceeds from issuance of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

1,100,000

1,100,000

Additional net proceeds from issuance of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

$947,000

$947,000

Underwriter's overallotment shares

428,700

90,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Significant_Accounting_Policie3

Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Segment
Significant Accounting Policies [Line Items]	'	'	'
Number of operating segment	1	'	'
Deferred offering costs reclassified to additional paid-in capital	$2,500,000	'	'
Deferred offering cost	617,706	'	'
Accrual for interest or penalties	0	0	'
Intangible asset impairments	0	0	0
Accrued liability related to registration rights obligations associated with the issuance of Series B preferred stock and certain notes payable	300,000	541,000	'
Loss in equity-method investment	-12,343	'	'
Other Assets [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Net receivable due from the joint venture	24,000	0	'
Patents [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Accumulated amortization of patents	56,000	41,000	'
Future amortization expense, 2018	26,800	'	'
Future amortization expense, 2019	23,600	'	'
Future amortization expense, 2020	17,100	'	'
Future amortization expense, 2021	14,300	'	'
Future amortization expense, 2022	11,600	'	'
Future amortization expense, 2023	11,600	'	'
Research and Development [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Loss in equity-method investment	12,000	'	'
Minimum [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Fixed assets, estimated useful lives	'5 years	'	'
Maximum [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Fixed assets, estimated useful lives	'7 years	'	'
Secondary Offering [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Reclassification of offering costs and underwriting discounts to additional paid-in-capital	1,800,000	'	'
Follow-On Offering [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Reclassification of offering costs and underwriting discounts to additional paid-in-capital	$3,700,000	'	'

Significant_Accounting_Policie4

Significant Accounting Policies - Computation of Basic Net Income (Loss) and Diluted Net Loss per Share Data (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Numerator:	'	'	'
Net income (loss)	($12,372,553)	($6,665,627)	($19,887,040)
Less gain in fair value of warrant liability	4,633,000	7,538,000	-10,388,000
Net (loss) for diluted earnings per share	($17,005,553)	($14,203,627)	($19,887,040)
Denominator:	'	'	'
Weighted-average basic common shares outstanding	4,665,316	1,342,174	1,274,153
Assumed conversion of dilutive securities:	'	'	'
Common stock purchase warrants	10,658	3,987	'
Potentially dilutive common shares	10,658	3,987	'
Denominator for diluted earnings per share-adjusted weighted-average shares	4,675,974	1,346,161	1,274,153
Basic net income (loss) per share	($2.65)	($4.97)	($15.61)
Diluted net loss per share	($3.64)	($10.55)	($15.61)

Significant_Accounting_Policie5

Significant Accounting Policies - Summary of Potentially Dilutive Adjustments to Weighted Average Number of Common Shares Excluded from Calculation (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Securities excluded from calculation	2,588,026	2,372,450	2,165,663
Series A Preferred Stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Securities excluded from calculation	'	352,614	352,614
Series B Preferred Stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Securities excluded from calculation	'	364,320	364,320
Warrants [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Securities excluded from calculation	1,701,984	1,102,176	888,739
Stock Options [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Securities excluded from calculation	873,542	553,340	559,990
Restricted Stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Securities excluded from calculation	7,500	'	'

Revenue_and_Accounts_Receivabl2

Revenue and Accounts Receivable - Schedule of Revenue by Payor Type (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'	'
Revenue	$6,609,957	$4,301,563	$3,019,407
Medicare [Member]	'	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'	'
Revenue	833,892	753,248	717,661
Direct Bill (Including Clinical Trials Clients) [Member]	'	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'	'
Revenue	3,843,010	1,594,509	350,290
Grants and Royalty [Member]	'	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'	'
Revenue	296,877	556,940	315,195
Insurance Carrier and All Others [Member]	'	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'	'
Revenue	$1,636,178	$1,396,866	$1,636,261

Revenue_and_Accounts_Receivabl3

Revenue and Accounts Receivable - Schedule of Accounts Receivable by Payor Type (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Allowance for doubtful accounts	($36,000)	($36,000)
Accounts receivable, net	1,567,039	850,545
Medicare [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, gross	408,856	193,024
Direct Bill (Including Clinical Trials Clients) [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, gross	628,830	339,763
Insurance Carrier and All Others [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, gross	$565,353	$353,758

Revenue_and_Accounts_Receivabl4

Revenue and Accounts Receivable - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Sites accounted for approximately 10% or more of our revenue	1	3	2
Clinical Testing [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Percentage of revenue	69.00%	58.00%	63.00%
Community Hospitals [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Percentage of revenue	36.00%	46.00%	29.00%
Community Hospitals [Member] | 10% or More Clinical Revenue [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Percentage of revenue	'	10.00%	18.00%
Clinical Trial Client [Member] | 10% or More Clinical Revenue [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Percentage of revenue	40.00%	13.00%	'
University Teaching Center [Member] | 10% or More Clinical Revenue [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Percentage of revenue	'	11.00%	'
Community Hospital Network [Member] | 10% or More Clinical Revenue [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Percentage of revenue	'	'	11.00%

Other_Current_Assets_Schedule_

Other Current Assets - Schedule of Other Current Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Other Current Asset [Abstract]	'	'
Inventory probes	$198,789	$233,767
Prepaid expenses	593,950	255,511
Grants receivable	71,877	'
Other assets, current	$864,616	$489,278

Lease_Commitments_Additional_I

Lease Commitments - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jan. 15, 2014	Dec. 31, 2013	Dec. 31, 2013
				Subsequent Event [Member]	Minimum [Member]	Maximum [Member]
Lease Disclosure [Line Items]	'	'	'	'	'	'
Lease agreement expiration date	28-Feb-18	'	'	'	'	'
Lease term	'10 years	'	'	'	'	'
Periodic rent increases per square foot per year	'	'	'	'	$1	$2
Security deposit for lease	300,000	'	'	'	'	'
Equipment under these capital leases, cost	403,288	'	'	'	'	'
Equipment under these capital leases, accumulated depreciation	26,454	'	'	'	'	'
Rent expense	550,882	516,173	517,667	'	'	'
Capital lease with future obligation	'	'	'	$7,615	'	'
Contractual due date	'	'	'	26-May-14	'	'

Lease_Commitments_Minimum_Futu

Lease Commitments - Minimum Future Lease Payments Under All Capital and Operating Leases (Detail) (USD $)	Dec. 31, 2013
Schedule Of Operating And Capital Leased Assets [Line Items]	'
2014	$679,830
2015	668,922
2016	624,078
2017	624,078
2018	106,176
Thereafter	118,190
Total minimum lease payments	2,821,274
Operating Leases [Member]	'
Schedule Of Operating And Capital Leased Assets [Line Items]	'
2014	613,121
2015	609,828
2016	564,984
2017	564,984
2018	47,082
Total minimum lease payments	2,399,999
Capital Leases [Member]	'
Schedule Of Operating And Capital Leased Assets [Line Items]	'
2014	66,709
2015	59,094
2016	59,094
2017	59,094
2018	59,094
Thereafter	118,190
Total minimum lease payments	421,275
Less amount representing interest	60,098
Present value of net minimum obligations	361,177
Less current obligation under capital lease	51,400
Long-term obligation under capital lease	$309,777

Notes_Payable_and_Lines_of_Cre2

Notes Payable and Lines of Credit - Summary of Short-Term and Long-Term Debt Obligations (Detail) (USD $)	Dec. 31, 2013	Apr. 10, 2013	Dec. 31, 2012	Dec. 31, 2011
Debt Instrument [Line Items]	'	'	'	'
Unamortized debt discount	'	'	($243,300)	'
Notes payable, Current Portion	22,298	'	3,836,567	'
Line of Credit, Principal Balance	6,000,000	'	3,000,000	'
Unamortized Debt Discount	'	-3,500,000	-128,800	-161,000
Line of Credit, Current Portion	6,000,000	'	2,871,200	'
Unamortized debt discount	'	'	-3,681,615	'
Notes payable, Long-Term	'	'	2,440,683	'
Lines of Credit, Long-Term	'	'	6,000,000	'
December 2011 Financing Transaction [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Notes payable, Current Portion	'	'	4,000,000	'
Notes payable, Long-Term	'	'	2,000,000	'
2012 Convertible Debt Financing Transaction [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Notes payable, Long-Term	'	'	3,000,000	'
Secured Note Payable [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Notes payable, Current Portion	22,298	'	79,867	'
Notes payable, Long-Term	'	'	22,298	'
December 2012 Bridge Financing Transaction [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Notes payable, Long-Term	'	'	1,000,000	'
Other Note Payable [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Notes payable, Long-Term	'	'	$100,000	'

Notes_Payable_and_Lines_of_Cre3

Notes Payable and Lines of Credit - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Apr. 10, 2013

Sep. 30, 2011

Dec. 31, 2013

Aug. 19, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2012

Oct. 31, 2012

Feb. 21, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Apr. 10, 2013

Dec. 31, 2013

Dec. 31, 2013

Apr. 10, 2013

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2014

Apr. 10, 2013

Dec. 31, 2013

Aug. 19, 2013

Dec. 31, 2012

Apr. 10, 2013

Apr. 10, 2013

Dec. 31, 2013

Apr. 10, 2013

Dec. 31, 2013

Dec. 31, 2013

Apr. 10, 2013

Feb. 22, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Apr. 10, 2013

Feb. 22, 2013

Apr. 10, 2013

Dec. 31, 2013

Apr. 10, 2013

Apr. 10, 2013

Dec. 07, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 07, 2012

Dec. 07, 2012

Dec. 31, 2013

Aug. 19, 2013

Apr. 10, 2013

Feb. 13, 2013

Dec. 31, 2013

Mar. 19, 2013

Dec. 31, 2012

Apr. 10, 2013

Apr. 10, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Sep. 25, 2012

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

Subsequent Event [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

NNJCA [Member]

NNJCA [Member]

NNJCA [Member]

NNJCA [Member]

Wells Fargo Bank [Member]

Wells Fargo Bank [Member]

Wells Fargo Bank [Member]

December 2011 Financing Transaction [Member]

December 2011 Financing Transaction [Member]

December 2011 Financing Transaction [Member]

December 2011 Financing Transaction [Member]

December 2011 Financing Transaction [Member]

December 2011 Financing Transaction [Member]

December 2011 Financing Transaction [Member]

December 2011 Financing Transaction [Member]

December 2011 Financing Transaction [Member]

December 2011 Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

December 2012 Bridge Financing Transaction [Member]

December 2012 Bridge Financing Transaction [Member]

December 2012 Bridge Financing Transaction [Member]

December 2012 Bridge Financing Transaction [Member]

December 2012 Bridge Financing Transaction [Member]

December 2012 Bridge Financing Transaction [Member]

December 2012 Bridge Financing Transaction [Member]

December 2012 Bridge Financing Transaction [Member]

Business Lines of Credit (DAM) [Member]

Business Lines of Credit (DAM) [Member]

Business Lines of Credit (DAM) [Member]

Business Lines of Credit (DAM) [Member]

Business Lines of Credit (DAM) [Member]

Business Lines of Credit (DAM) [Member]

Business Lines of Credit (DAM) [Member]

Other Note Payable [Member]

Other Note Payable [Member]

Other Note Payable [Member]

Secured Note Payable [Member]

Secured Note Payable [Member]

Secured Note Payable [Member]

Financial Guarantee [Member]

IPO [Member]

Financial Guarantee [Member]

IPO [Member]

Subsequent Event [Member]

IPO [Member]

John Pappajohn [Member]

John Pappajohn [Member]

NNJCA [Member]

NNJCA [Member]

Dr. Pecora [Member]

IPO [Member]

IPO [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

Mr. Mark Oman [Member]

IPO [Member]

IPO [Member]

John Pappajohn [Member]

John Pappajohn [Member]

IPO [Member]

Financial Guarantee [Member]

Financial Guarantee [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Borrowings from utilization of line of credit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6,000,000

$6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument spread on variable rate

'

'

6.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

1.75%

'

1.75%

'

6.25%

'

'

'

'

'

'

'

'

'

'

6.25%

'

'

'

'

'

'

'

'

'

6.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument maturity date

'

'

'

'

'

'

'

'

25-Mar-14

'

'

'

'

'

'

'

1-Apr-14

'

1-Apr-16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15-Aug-13

'

'

'

'

'

'

'

'

'

Interest on line of credit at end period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted cash required as collateral

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Secured note interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.50%

'

'

'

18.00%

Secured note outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

22,298

102,165

'

Repayment of secured note

'

'

'

'

'

'

'

'

22,298

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining debt discount after conversion

3,500,000

'

'

'

128,800

161,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued fee on debt instrument

419,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

130,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

52,500

'

'

'

'

'

'

'

'

'

Recognizable conversion feature in converted debt

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt outstanding under credit agreement

'

'

'

'

'

'

'

'

'

500,000

'

'

'

1,500,000

'

'

'

'

'

'

0

'

6,000,000

'

'

4,000,000

'

1,500,000

500,000

3,000,000

'

'

'

'

'

'

1,750,000

'

1,250,000

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of outstanding debt to common stock

9,634,300

'

9,634,300

'

'

'

1,000,000

'

'

'

'

'

500,000

'

'

'

'

'

'

4,500,000

'

'

'

'

4,000,000

'

500,000

'

'

3,000,000

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

1,000,000

1,000,000

'

'

'

'

'

'

'

'

'

'

Common shares

963,430

'

12,596,066

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

450,000

'

'

'

'

'

'

450,000

'

'

300,000

'

'

'

'

'

'

'

'

'

100,000

100,000

'

'

'

'

'

'

'

100,000

'

'

'

'

'

13,430

'

'

'

'

'

Conversion price of notes

'

'

'

'

'

'

'

'

'

'

'

$10

'

'

'

$10

'

'

'

'

'

'

'

$10

'

'

'

'

'

'

'

'

'

$10

$10

'

'

'

'

'

'

$42.50

'

$10

$10

'

'

'

'

'

'

'

'

$10

$10

'

'

'

'

'

Outstanding balance, repaid

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate at period end

'

'

9.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.50%

'

'

'

'

'

'

'

'

'

9.50%

'

'

'

'

'

'

'

'

'

9.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument amount paid upon conversion of the notes

'

'

32,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

IPO funding period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'181 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants duration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase aggregate common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,059

'

'

'

'

'

'

'

'

'

2,353

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock warrants, exercise price

'

$4

$12.26

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$42.50

'

'

'

$15

'

'

'

'

'

$42.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding per share

'

'

'

'

'

'

'

'

'

$15

$15

'

'

'

$4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15

'

'

'

'

'

'

'

'

$15

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit outstanding under credit agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

2,000,000

3,000,000

'

'

'

'

'

'

'

Line of credit, indebtedness

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

Line of credit, repaid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Annual interest rate equal to prime rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

Notes payable, Long-Term

'

'

'

'

2,440,683

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

22,298

'

Accrued interest on notes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$34,300

'

'

'

Conversion price of loan into common stock

'

'

'

'

'

'

20.00%

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

IPO or merger price

$10

'

'

'

'

'

$53.12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

'

'

'

'

'

'

'

'

'

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price discount on IPO or merger price

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

IPO or merger price

'

'

'

'

'

'

$53.13

$53.13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes_Payable_and_Lines_of_Cre4

Notes Payable and Lines of Credit - Conversion of Indebtedness into Shares of Common Stock (Detail) (USD $)	0 Months Ended	12 Months Ended	0 Months Ended
	Apr. 10, 2013	Dec. 31, 2013	Apr. 10, 2013	Apr. 10, 2013	Apr. 10, 2013	Dec. 07, 2012	Apr. 10, 2013	Feb. 13, 2013	Apr. 10, 2013
			December 2011 Financing Transaction [Member]	2012 Convertible Debt Financing Transaction [Member]	December 2012 Bridge Financing Transaction [Member]	December 2012 Bridge Financing Transaction [Member]	Business Lines of Credit (DAM) [Member]	Business Lines of Credit (DAM) [Member]	Other Notes Payable and Accrued Interest [Member]
Debt Conversion [Line Items]	'	'	'	'	'	'	'	'	'
Converted Amount	$9,634,300	$9,634,300	$4,500,000	$3,000,000	$1,000,000	'	$1,000,000	$1,000,000	$134,300
Common shares	963,430	12,596,066	450,000	300,000	100,000	100,000	100,000	'	13,430

Notes_Payable_and_Lines_of_Cre5

Notes Payable and Lines of Credit - Loss on Debt and Warrant Restructuring (Detail) (USD $)	12 Months Ended
	Dec. 31, 2012
Debt Instrument [Line Items]	'
Loss on debt and warrant restructuring	$1,862,012
2012 Convertible Debt Financing Transaction [Member] | Restated [Member]	'
Debt Instrument [Line Items]	'
Loss on debt and warrant restructuring	1,506,512
Line of Credit [Member] | Amendment [Member]	'
Debt Instrument [Line Items]	'
Loss on debt and warrant restructuring	268,000
Line of Credit [Member] | Settlement [Member]	'
Debt Instrument [Line Items]	'
Loss on debt and warrant restructuring	-129,500
2011 Convertible Debt Financing Transaction [Member] | Amendment [Member]	'
Debt Instrument [Line Items]	'
Loss on debt and warrant restructuring	545,000
2011 Convertible Debt Financing Transaction [Member] | Settlement [Member]	'
Debt Instrument [Line Items]	'
Loss on debt and warrant restructuring	($328,000)

Letter_of_Credit_Additional_In

Letter of Credit - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Stand-by letter of credit	$300,000
Letter of credit facility restricted amount	$50,000

Fixed_Assets_Fixed_Assets_Summ

Fixed Assets - Fixed Assets Summary by Major Classifications (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property Plant And Equipment [Abstract]	'	'
Equipment	$2,513,066	$1,914,215
Furniture and fixtures	461,119	461,119
Leasehold improvements	595,689	583,592
Gross	3,569,874	2,958,926
Less accumulated depreciation	-2,305,250	-1,994,003
Net fixed assets	$1,264,624	$964,923

Income_Taxes_Income_Tax_Reconc

Income Taxes - Income Tax Reconciliation (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Income tax benefit at federal statutory rate	($4,563,000)	($2,333,000)	($6,960,000)
State tax provision, net of federal tax benefit	-359,000	-661,000	-604,000
Tax credits	-126,000	-82,000	-57,000
Stock based compensation permanent differences	229,000	85,000	43,000
Derivative warrant permanent differences	-1,622,000	-1,926,000	3,636,000
Debt and warrant conversion costs permanent difference	4,118,000	'	'
State tax benefit of State of New Jersey NOL	-664,000	'	'
Change in valuation allowance	2,356,000	4,858,000	5,320,000
Change in uncertain tax positions	'	'	-1,395,000
Other	-33,000	59,000	17,000
Provision for income taxes	($663,900)	'	'
Income tax benefit at federal statutory rate	35.00%	35.00%	35.00%
State tax provision, net of federal tax benefit	2.80%	9.50%	3.00%
Tax credits	1.00%	1.10%	0.30%
Stock based compensation permanent differences	-1.80%	-1.20%	-0.20%
Derivative warrant permanent differences	12.40%	26.00%	-18.20%
Debt and warrant conversion costs permanent difference	-31.60%	'	'
State tax benefit of State of New Jersey NOL	5.10%	'	'
Change in valuation allowance	-18.10%	-70.20%	-26.80%
Change in uncertain tax positions	0.00%	0.00%	7.00%
Other	0.30%	-0.20%	-0.10%
Provision for income taxes	5.10%	0.00%	0.00%

Income_Taxes_Components_of_App

Income Taxes - Components of Approximate Deferred Tax (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carryforwards	$17,140,000	$15,134,000
Accruals and reserves	509,000	486,000
Non-qualified stock options	877,000	844,000
Research and development tax credits	603,000	477,000
Derivative warrant liability	26,000	26,000
Investment in joint venture	163,000	'
Other	5,000	7,000
Total deferred tax assets	19,323,000	16,974,000
Less valuation allowance	-19,303,000	-16,947,000
Net deferred tax assets	20,000	27,000
Deferred tax liabilities	'	'
Fixed assets	-20,000	-27,000
Net deferred taxes	'	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended		12 Months Ended	0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jan. 31, 2014
			New Jersey [Member]	New Jersey [Member]
				Subsequent Event [Member]
Income Tax [Line Items]	'	'	'	'
Net operating loss carryforward	$44,000,000	'	$8,018,107	$22,301,643
Net operating loss carryforward, expiration date	'Begin to expire in 2027	'	'	'
Proceeds from sale of operating loss carryforward	'	'	663,900	1,813,941
Uncertain tax positions	$0	$0	'	'

Capital_Stock_Additional_Infor

Capital Stock - Additional Information (Detail) (USD $)

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

Oct. 28, 2013

Apr. 10, 2013

Dec. 31, 2013

Oct. 31, 2013

Dec. 31, 2012

Aug. 19, 2013

Dec. 31, 2013

Sep. 05, 2013

Oct. 28, 2013

Apr. 10, 2013

Apr. 10, 2013

Dec. 31, 2013

Dec. 31, 2012

Apr. 10, 2013

Dec. 31, 2013

Dec. 31, 2012

Secondary Offering [Member]

Secondary Offering [Member]

Secondary Offering [Member]

Follow-On Offering [Member]

Cleveland Clinic [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Common stock, shares issued

3,286,700

690,000

9,275,384

10,000

1,349,936

1,500,000

'

'

3,286,700

2,000

'

'

'

'

'

'

Underwriter's overallotment shares

428,700

90,000

'

'

'

'

'

'

428,700

'

'

'

'

'

'

'

Common stock sold at IPO, price per share

$14

$10

'

'

'

$10

'

'

$14

'

'

'

'

'

'

'

Gross proceeds from public offering

$46,000,000

$6,900,000

'

'

'

$15,000,000

'

'

$46,000,000

'

'

'

'

'

'

'

Number of shares converted to common stock

'

1,287,325

'

'

'

'

'

'

'

'

376,525

'

'

910,800

'

'

Net proceeds from secondary public offering

'

'

'

'

'

13,300,000

'

'

42,300,000

'

'

'

'

'

'

'

Additional common stock sold at public offering

'

'

'

'

'

'

105,000

105,000

'

'

'

'

'

'

'

'

Gross proceeds from issuance of shares

'

'

'

'

'

'

1,100,000

1,100,000

'

'

'

'

'

'

'

'

Additional net proceeds from issuance of shares

'

'

'

'

'

'

$947,000

$947,000

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

'

'

9,764,000

'

'

'

'

'

'

'

'

588,000

588,000

'

2,000,000

2,000,000

Stock_Option_Plans_Additional_

Stock Option Plans - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Oct. 10, 2013

Apr. 10, 2013

Apr. 05, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Feb. 28, 2014

Jan. 06, 2014

Mar. 31, 2013

Feb. 28, 2014

Dec. 31, 2011

Dec. 31, 2011

Oct. 10, 2013

Apr. 05, 2013

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2013

Oct. 10, 2013

Oct. 10, 2013

Oct. 10, 2013

Jan. 06, 2014

Dec. 31, 2013

Oct. 12, 2012

Mar. 31, 2013

Dec. 31, 2013

Feb. 28, 2014

Dec. 31, 2013

Apr. 01, 2010

Apr. 29, 2008

Dec. 31, 2013

Mar. 31, 2013

Jan. 06, 2014

Oct. 31, 2013

Dec. 31, 2013

Oct. 10, 2013

Dec. 31, 2013

Dec. 31, 2013

Stock_Plan

Subsequent Event [Member]

Subsequent Event [Member]

General and Administrative [Member]

General and Administrative [Member]

Minimum [Member]

Maximum [Member]

Chief Executive Officer [Member]

Non-Employees [Member]

Non-Employees [Member]

Non-Employees [Member]

Non-Employees [Member]

Non-Employees [Member]

Employees [Member]

Vice President Research and Development [Member]

Non-employee Director [Member]

Chairman of Audit Committee [Member]

Chairman of Board [Member]

2011 Equity Incentive Plan [Member]

2011 Equity Incentive Plan [Member]

2011 Equity Incentive Plan [Member]

2011 Equity Incentive Plan [Member]

2011 Equity Incentive Plan [Member]

2008 Stock Option Plan [Member]

2008 Stock Option Plan [Member]

2008 Stock Option Plan [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock Awards [Member]

Strike Price of $25.00 or More [Member]

Strike Price of $12.50 [Member]

March 31, 2014 [Member]

Subsequent Event [Member]

Subsequent Event [Member]

April 1, 2014 [Member]

Chief Executive Officer [Member]

Dr. Chaganti [Member]

April 1, 2014 [Member]

Subsequent Event [Member]

Mr. Thompson, Chairman Audit Committee [Member]

Employees [Member]

Non-employee Director [Member]

Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of equity incentive plans

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock shares authorized for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

350,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock reserved for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

550,000

251,475

'

'

'

'

'

'

'

'

Options granted maximum exercisable period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

Shares available for future awards

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,594

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

Restricted stock awarded under Stock Option Plans

'

'

'

7,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock appreciation rights

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of shares under stock options plans

'

'

'

48,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding stock options

'

'

336,300

873,542

'

35,650

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options exercise price

'

'

'

'

'

'

'

'

'

'

'

$4

$4.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options strike price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25

$12.50

Exchange options for number of options held with exercise price equal to initial public offering price, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60.00%

80.00%

Price per share on equity offering

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

$10

Initial public offering exercisable lower price range

'

'

$12.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial public offering exercisable upper price range

'

'

$33.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial offering, options exchanged

'

'

242,070

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price option

$15.39

'

$10

'

'

'

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

$15.39

'

'

'

'

'

'

$15.89

'

'

'

'

'

'

'

'

'

'

'

Approved options issued

'

'

53,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options issued, exercise price

'

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock awarded under Stock Option Plans additional issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of common stock

'

'

'

$13.78

$9.60

$33.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from option exercises

'

'

'

$1,640

'

'

'

$2,020

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options exercised, intrinsic value

'

'

'

1,630

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to nonvested stock options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

94,359

190,500

'

4,176,050

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to nonvested stock options granted expect to recognize, period (in years)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year 9 months 11 days

'6 months

'

'3 years 11 months 1 day

'

'

'

'

'

'

'

'

'

'

'

'

'3 years 15 days

'

'

'

'

'

'

'

Options exchanged

'

'

'

164

'

'

'

'

'

'

'

'

'

'

48,000

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of options exchanged

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

$15.39

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to unvested restricted stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

61,913

'

'

'

'

'

'

'

Number of shares outstanding

'

'

'

873,542

553,340

559,990

511,660

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,500

'

'

'

'

'

'

'

Number of shares vested

2,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500

'

'

'

'

'

'

'

Issuance of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

25,000

2,500

5,000

5,000

'

'

Grant date fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15.39

$12.55

'

'

'

Employee stock option purchased

12,312

'

'

426,762

2,400

67,615

'

202

100,000

'

'

'

'

200,000

'

'

'

'

'

'

10,000

10,000

'

'

'

'

90,000

'

200,000

'

'

'

'

'

'

'

'

'

'

'

Options expired

'10 years

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted shares of common stock issued to Chief Executive Officer

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options vesting period

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options granted, total

60,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual base fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

10,000

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued to purchase shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock and options vesting period description

'

'

'

'

'

'

'

'

'The restricted stock and the options will each vest in two equal installments on the one year anniversary and the two year anniversary of the date on which Mr. Pappajohn becomes the Chairman of the Board.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation expense

'

'

'

$646,983

$915,361

$1,093,117

'

'

'

$124,000

$83,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Option_Plans_Summary_of_

Stock Option Plans - Summary of Employee and Nonemployee Stock Option Activity (Detail) (USD $)	0 Months Ended	12 Months Ended
	Oct. 10, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Options Outstanding, Number of Shares Outstanding	'	'	'	'	'
Outstanding, beginning balance	'	553,340	559,990	511,660	'
Granted	12,312	426,762	2,400	67,615	'
Exercised	'	-164	'	'	'
Cancelled or expired	'	-106,396	-9,050	-19,285	'
Outstanding, ending balance	'	873,542	553,340	559,990	511,660
Exercisable	'	413,103	'	'	'
Options Outstanding, Weighted Average Exercise Price	'	'	'	'	'
Outstanding, beginning balance	'	$12.76	$12.85	$10.90	'
Granted	'	$14.57	$33.80	$26.73	'
Exercised	'	$10	'	'	'
Cancelled or expired	'	$20.46	$23.43	$11.78	'
Outstanding, ending balance	'	$10.83	$12.76	$12.85	$10.90
Exercisable	'	$7.21	'	'	'
Weighted-Average Remaining Contractual Term (in years)	'	'	'	'	'
Outstanding	'	'7 years 9 months	'7 years 1 month 17 days	'8 years 1 month 6 days	'8 years 11 months 19 days
Exercisable	'	'6 years 29 days	'	'	'
Aggregate Intrinsic Value	'	'	'	'	'
Outstanding, beginning balance	'	$1,142,432	$11,737,710	$1,693,760	'
Outstanding, ending balance	'	3,138,539	1,142,432	11,737,710	1,693,760
Exercisable	'	$2,726,095	'	'	'

Stock_Option_Plans_Summary_of_1

Stock Option Plans - Summary of Outstanding and Vested Stock Options Granted (Detail) (USD $)	0 Months Ended	12 Months Ended
	Apr. 05, 2013	Dec. 31, 2013	Dec. 31, 2011
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise Price	$33.80	'	'
Number of Shares Options Outstanding	336,300	873,542	35,650
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'7 years 9 months	'
Weighted-Average Exercise Price, Options Outstanding	'	$10.83	'
Number of Shares Options Vested and Exercisable	'	413,103	'
Weighted-Average Exercise Price, Options Vested and Exercisable	'	$7.21	'
Exercise Price 4.00 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise Price	'	$4	'
Number of Shares Options Outstanding	'	175,000	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'5 years 3 months 29 days	'
Weighted-Average Exercise Price, Options Outstanding	'	$4	'
Number of Shares Options Vested and Exercisable	'	175,000	'
Weighted-Average Exercise Price, Options Vested and Exercisable	'	$4	'
Exercise Price 4.80 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise Price	'	$4.80	'
Number of Shares Options Outstanding	'	33,340	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'6 years 18 days	'
Weighted-Average Exercise Price, Options Outstanding	'	$4.80	'
Number of Shares Options Vested and Exercisable	'	26,936	'
Weighted-Average Exercise Price, Options Vested and Exercisable	'	$4.80	'
Exercise Price 10.00 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise Price	'	$10	'
Number of Shares Options Outstanding	'	291,990	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'6 years 9 months 22 days	'
Weighted-Average Exercise Price, Options Outstanding	'	$10	'
Number of Shares Options Vested and Exercisable	'	204,380	'
Weighted-Average Exercise Price, Options Vested and Exercisable	'	$10	'
Exercise Price 11.75 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise Price	'	$11.75	'
Number of Shares Options Outstanding	'	5,600	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'9 years 3 months 15 days	'
Weighted-Average Exercise Price, Options Outstanding	'	$11.75	'
Number of Shares Options Vested and Exercisable	'	'	'
Weighted-Average Exercise Price, Options Vested and Exercisable	'	$11.75	'
Exercise Price 12.50 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise Price	'	$12.50	'
Number of Shares Options Outstanding	'	200	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'6 years 11 months 9 days	'
Weighted-Average Exercise Price, Options Outstanding	'	$12.50	'
Number of Shares Options Vested and Exercisable	'	120	'
Weighted-Average Exercise Price, Options Vested and Exercisable	'	$12.50	'
Exercise Price 12.55 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise Price	'	$12.55	'
Number of Shares Options Outstanding	'	10,000	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'9 years 11 months 12 days	'
Weighted-Average Exercise Price, Options Outstanding	'	$12.55	'
Number of Shares Options Vested and Exercisable	'	'	'
Weighted-Average Exercise Price, Options Vested and Exercisable	'	$12.55	'
Exercise Price 13.81 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise Price	'	$13.81	'
Number of Shares Options Outstanding	'	3,000	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'9 years 10 months 24 days	'
Weighted-Average Exercise Price, Options Outstanding	'	$13.81	'
Number of Shares Options Vested and Exercisable	'	'	'
Weighted-Average Exercise Price, Options Vested and Exercisable	'	$13.81	'
Exercise Price 14.18 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise Price	'	$14.18	'
Number of Shares Options Outstanding	'	5,500	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'9 years 10 months 17 days	'
Weighted-Average Exercise Price, Options Outstanding	'	$14.18	'
Number of Shares Options Vested and Exercisable	'	'	'
Weighted-Average Exercise Price, Options Vested and Exercisable	'	$14.18	'
Exercise Price 15.39 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise Price	'	$15.39	'
Number of Shares Options Outstanding	'	348,912	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'9 years 9 months 7 days	'
Weighted-Average Exercise Price, Options Outstanding	'	$15.39	'
Number of Shares Options Vested and Exercisable	'	6,667	'
Weighted-Average Exercise Price, Options Vested and Exercisable	'	$15.39	'

Stock_Option_Plans_WeightedAve

Stock Option Plans - Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employees [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Volatility	76.60%	77.39%	76.13%
Risk free interest rate	1.79%	1.43%	2.67%
Dividend yield	'	'	'
Term (years)	'6 years 1 month 21 days	'6 years 6 months	'6 years 5 months 9 days
Weighted-average fair value of options granted during the period	$9.85	$23.35	$10.60
Non-Employees [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Volatility	75.68%	75.01%	75.45%
Risk free interest rate	1.53%	1.26%	2.85%
Dividend yield	'	'	'
Term (years)	'7 years 8 months 5 days	'8 years 3 months 11 days	'9 years 2 months 23 days

Stock_Option_Plans_Effects_of_

Stock Option Plans - Effects of Stock-Based Compensation Related to Stock Option and Restricted Stock Awards (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'
Total stock-based compensation	$735,145	$915,361	$943,117
Cost of Revenues [Member]	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'
Total stock-based compensation	41,470	11,753	9,603
Research and Development [Member]	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'
Total stock-based compensation	114,189	460,321	423,950
General and Administrative [Member]	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'
Total stock-based compensation	516,127	297,175	263,693
Sales and Marketing [Member]	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'
Total stock-based compensation	$63,359	$146,112	$245,871

Warrants_Additional_Informatio

Warrants - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Oct. 08, 2013

Sep. 30, 2013

Sep. 27, 2013

Sep. 10, 2013

Jul. 08, 2013

Jul. 06, 2013

Apr. 29, 2013

Apr. 10, 2013

Sep. 27, 2012

Sep. 06, 2012

Aug. 14, 2012

Feb. 29, 2012

Sep. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Jan. 31, 2013

Oct. 07, 2013

Oct. 07, 2013

Mar. 31, 2012

Mar. 31, 2011

Feb. 22, 2013

Dec. 31, 2013

Dec. 31, 2013

Oct. 31, 2012

Dec. 31, 2012

Dec. 31, 2011

Feb. 11, 2013

Oct. 22, 2012

Oct. 22, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2012

Feb. 22, 2013

Dec. 31, 2013

Oct. 31, 2012

Feb. 22, 2013

Feb. 11, 2013

Dec. 31, 2012

Oct. 31, 2012

Dec. 31, 2012

Subsequent Event [Member]

Maximum [Member]

Minimum [Member]

Line of Credit [Member]

Line of Credit [Member]

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

December 2012 Bridge Financing Transaction [Member]

Financing Arrangements [Member]

Financing Arrangements [Member]

Financing Arrangements [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

Mr. Mark Oman [Member]

Certain Warrant Holders [Member]

Mr.Pappajohn [Member]

Related Parties [Member]

Related Parties [Member]

Maximum [Member]

Debt Guarantee [Member]

Debt Guarantee [Member]

Debt Guarantee [Member]

Bridge Loan [Member]

2012 Convertible Debt Financing Transaction [Member]

December 2012 Bridge Financing Transaction [Member]

Financing Arrangements [Member]

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

2012 Convertible Debt Financing Transaction [Member]

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants granted

'

'

'

'

'

'

'

'

'

'

4,706

28,235

'

'

'

'

'

'

'

'

15,000

60,000

'

'

2,353

20,669

112,940

'

'

'

'

1,051,506

'

'

23,529

4,118

'

9,412

2,941

'

4,000

114,510

28,235

Fair value of warrants at the date of issue

'

'

'

'

'

'

'

'

'

'

'

'

$6,415,000

$144,000

'

'

'

'

'

'

$306,000

$1,019,000

$221,000

'

$47,000

$606,000

$1,522,000

$951,000

'

$298,000

'

$1,555,000

$0

$831,000

$837,000

'

'

$267,000

'

'

$69,000

$4,090,000

$1,107,000

Warrants issued to a consultant for services provided

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase common stock, issued

'

'

'

'

'

'

'

'

65,328

70,598

'

'

228,288

70,598

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,157

'

'

'

'

'

'

'

'

'

114,030

'

'

'

Warrants exercise price

'

'

'

'

'

'

'

'

'

'

'

'

$4

$12.26

'

'

'

'

'

'

'

'

'

$42.50

$42.50

'

'

'

'

'

$42.50

'

'

'

'

$15

'

'

'

'

'

'

'

Warrants surrendered

23,188

14,313

'

'

'

2,072

'

'

'

'

'

'

'

'

193,176

'

'

'

'

'

'

'

'

'

'

37,646

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants amended

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,294

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, lock-up agreement period

'

'

'

'

'

'

'

'

'180 days

'180 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

117,902

54,910

3,546

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised, value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

690,227

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, expired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,164

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Price per share on equity offering

'

'

'

'

'

'

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum IPO price description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'If our final IPO price was below $15.00, there would be no further adjustment to the price or number of shares covered by the warrants held by him.

'

'

'

'

'

'

Final IPO price to determine exercise price of the warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjusted exercise price of warrants on initial public offerings

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issuable on exercise of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

838,889

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants effected with adjusted exercise price

'

'

'

'

'

'

'

1,656,860

'

'

'

'

'

1,656,860

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds form warrants exercised

'

'

'

'

$96,000

'

$96,000

'

'

'

'

'

'

$192,000

$635,227

$49,999

'

$950

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised to purchase common stock

33,868

30,034

'

'

24,000

6,000

24,000

'

'

'

'

'

'

'

'

'

'

95

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock per share value on warrant exercised

'

$10

'

'

$4

$4

$4

'

'

'

'

'

'

'

'

'

'

$10

$14.10

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued

10,680

15,721

'

'

'

3,928

'

'

'

'

'

'

'

9,412

476,688

146,553

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant outstanding

'

42,468

'

'

'

'

'

'

'

'

'

'

'

1,797,114

1,102,176

888,739

745,732

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Extended expiration date of warrant

'

'

'11 days

'17 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants_Summary_of_Warrant_Ac

Warrants - Summary of Warrant Activity (Detail) (USD $)	0 Months Ended			1 Months Ended	12 Months Ended
	Oct. 08, 2013	Sep. 30, 2013	Jul. 06, 2013	Sep. 30, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	$4	$12.26	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	1,102,176	888,739	745,732
Warrants Issued	10,680	15,721	3,928	'	9,412	476,688	146,553
Warrants Exercised	'	'	'	'	-117,902	-54,910	-3,546
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	42,468	'	'	1,797,114	1,102,176	888,739
Warrants Surrendered	-23,188	-14,313	-2,072	'	'	-193,176	'
Warrants Expired	'	'	'	'	-35,461	-15,165	'
IPO Adjustments	'	'	'	'	838,889	'	'
Warrant Issued With [Member] | Warrants Other Warrants [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$12.38	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	293,617	356,367	131,625
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	-83,868	-51,098	-3,546
Warrants Amended	'	'	'	'	'	'	228,288
Warrants Outstanding, Ending Balance	'	'	'	'	1,705,984	293,617	356,367
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	-35,461	-11,652	'
IPO Adjustments	'	'	'	'	1,531,696	'	'
Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$10	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	808,559	532,372	614,107
Warrants Issued	'	'	'	'	9,412	476,688	146,553
Warrants Exercised	'	'	'	'	-34,034	-3,812	'
Warrants Amended	'	'	'	'	'	'	-228,288
Warrants Outstanding, Ending Balance	'	'	'	'	91,130	808,559	532,372
Warrants Surrendered	'	'	'	'	'	-193,176	'
Warrants Expired	'	'	'	'	'	-3,513	'
IPO Adjustments	'	'	'	'	-692,807	'	'
Debt Guarantee [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$4	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	228,288	228,288	'
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	-54,000	'	'
Warrants Amended	'	'	'	'	'	'	228,288
Warrants Outstanding, Ending Balance	'	'	'	'	174,288	228,288	228,288
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	'	'	'
Debt Guarantee [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$10	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	'	'
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	237,500	'	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	237,500	'	'
Debt Guarantee [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$15	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	'	'
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	585,645	'	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	585,645	'	'
Debt Guarantee [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$10	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	'	'
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	12,500	'	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	12,500	'	'
Debt Guarantee [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$25	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	'	228,288
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	-228,288
Warrants Outstanding, Ending Balance	'	'	'	'	'	'	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	'	'	'
Debt Guarantee [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$25	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	212,000	212,000	212,000
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	212,000	212,000
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-212,000	'	'
Debt Guarantee [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$25	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	100,000	100,000	100,000
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	100,000	100,000
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-100,000	'	'
Debt Guarantee [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$32.45	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	40,000	40,000	'
Warrants Issued	'	'	'	'	'	'	40,000
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	40,000	40,000
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-40,000	'	'
Debt Guarantee [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$42.50	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	38,392	'	'
Warrants Issued	'	'	'	'	'	75,392	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	38,392	'
Warrants Surrendered	'	'	'	'	'	-37,000	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-38,392	'	'
Debt Guarantee [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$42.50	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	37,000	'	'
Warrants Issued	'	'	'	'	'	37,000	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	37,000	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-37,000	'	'
Series A Preferred Stock [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$4	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	7,325	7,325
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	-3,812	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	'	7,325
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	-3,513	'
IPO Adjustments	'	'	'	'	'	'	'
Series A Preferred Stock [Member] | Instrument Type One [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$10.75	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	30,000	30,000
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	-30,000	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	'	30,000
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	'	'	'
Series A Preferred Stock [Member] | Instrument Type Two [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$14.10	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	65,329	89,214	89,214
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	-29,868	-18,616	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	65,329	89,214
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	-35,461	-5,269	'
IPO Adjustments	'	'	'	'	'	'	'
Series B Preferred Stock [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$10	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	'	'
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	-34,034	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	18,430	'	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	52,464	'	'
Series B Preferred Stock [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$25	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	52,464	52,464	52,464
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	52,464	52,464
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-52,464	'	'
Financing [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$10	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	'	'
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	243,334	'	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	243,334	'	'
Financing [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$14.10	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	8,865	12,411
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	-2,482	-3,546
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	'	8,865
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	-6,383	'
IPO Adjustments	'	'	'	'	'	'	'
Financing [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$15	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	'	'
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	436,079	'	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	436,079	'	'
Consulting [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$10	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	'	'
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	29,138	'	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	29,138	'	'
Financing [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$10	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	'	'
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	60,000	'	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	60,000	'	'
Financing [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$25	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	60,000	60,000	'
Warrants Issued	'	'	'	'	'	'	60,000
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	60,000	60,000
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-60,000	'	'
Financing [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$42.50	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	75,294	42,353	'
Warrants Issued	'	'	'	'	'	189,117	42,353
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	75,294	42,353
Warrants Surrendered	'	'	'	'	'	-156,176	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-75,294	'	'
Financing [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$42.50	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	54,314	'	'
Warrants Issued	'	'	'	'	2,941	54,314	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	54,314	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-57,255	'	'
Financing [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$42.50	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	120,865	'	'
Warrants Issued	'	'	'	'	6,471	120,865	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	120,865	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-127,336	'	'
Consulting [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$10	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	'	'	'
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	200	'	'
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	200	'	'
Consulting [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$12.50	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	4,030	4,030	4,030
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	4,030	4,030
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-4,030	'	'
Consulting [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$14.10	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	10,000	10,000	10,000
Warrants Issued	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	10,000	10,000
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-10,000	'	'
Consulting [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$25	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	200	200	'
Warrants Issued	'	'	'	'	'	'	200
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	200	200
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-200	'	'
Consulting [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants, Exercise Price	'	'	'	'	$25	'	'
Warrants Outstanding, Beginning Balance	'	'	'	'	4,000	4,000	'
Warrants Issued	'	'	'	'	'	'	4,000
Warrants Exercised	'	'	'	'	'	'	'
Warrants Amended	'	'	'	'	'	'	'
Warrants Outstanding, Ending Balance	'	'	'	'	'	4,000	4,000
Warrants Surrendered	'	'	'	'	'	'	'
Warrants Expired	'	'	'	'	'	'	'
IPO Adjustments	'	'	'	'	-4,000	'	'

Warrants_Summary_of_Warrant_Ac1

Warrants - Summary of Warrant Activity (Parenthetical) (Detail) (USD $)	0 Months Ended
	Apr. 10, 2013	Dec. 31, 2013	Feb. 11, 2013
			IPO [Member]
Class of Warrant or Right [Line Items]	'	'	'
Share price of warrants held by related party	'	'	$15
Warrants held by director in total	'	'	530,022
Share price of common stock at the completion of IPO	$10	'	'
Shares issuable on exercise of warrants outstanding	838,889	'	'
Number of warrants effected with adjusted exercise price	1,656,860	1,656,860	'

Fair_Value_of_Warrants_Assumpt

Fair Value of Warrants - Assumptions Used in Computing Fair Value of Derivative Warrants (Detail) (USD $)	1 Months Ended		0 Months Ended	1 Months Ended		12 Months Ended		0 Months Ended	1 Months Ended		0 Months Ended	1 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Apr. 05, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Apr. 05, 2013	Dec. 31, 2013	Dec. 31, 2012	Apr. 05, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2011
	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	Financing [Member]	Financing [Member]	Financing [Member]	Financing [Member]	Financing [Member]	Consulting [Member]	Consulting [Member]	Consulting [Member]	Debt Guarantee [Member]	Debt Guarantee [Member]	Debt Guarantee [Member]	Debt Guarantee [Member]	Debt Guarantee [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Exercise Price	$10	$9.60	$13.21	$10	$9.60	$13.34	$23.69	$10	$10	$9.60	$13.56	$10	$28.78	$9.60	$32.45
Expected life (years)	'1 year 11 months 1 day	'2 years 11 months 1 day	'8 years 3 months 18 days	'2 years 3 months	'6 years 7 months 28 days	'9 years 9 months 11 days	'6 years 9 months 22 days	'2 years 3 months 29 days	'2 years 1 month 21 days	'2 years 5 months 23 days	'2 years 5 months 1 day	'9 months 29 days	'2 years 7 months 28 days	'4 years 7 months 28 days	'5 years
Expected volatility	59.26%	61.44%	73.22%	64.40%	73.38%	74.70%	77.74%	63.20%	62.63%	63.29%	66.37%	57.33%	67.71%	80.05%	77.35%
Risk-free interest rate	0.38%	0.36%	1.44%	0.38%	1.06%	1.95%	1.19%	0.27%	0.38%	0.28%	0.32%	0.13%	0.37%	0.82%	1.76%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Fair_Value_of_Warrants_Additio

Fair Value of Warrants - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Class of Warrant or Right [Line Items]	'	'	'
Fair value of warrants issue price	$13.78	$9.60	$33.80
Minimum [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Fair value of stock prices in computing fair value for warrants issued	$9.60	$9.60	$11.90
Maximum [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Fair value of stock prices in computing fair value for warrants issued	$20.26	$33.80	$33.80

Fair_Value_of_Warrants_Summary

Fair Value of Warrants - Summary of Derivative Warrant Activity (Detail) (USD $)	0 Months Ended	12 Months Ended
	Apr. 10, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Class of Warrant or Right [Line Items]	'	'	'	'
Beginning balance	'	$12,549,000	$11,113,000	$4,270,000
Fair value of warrants issued	'	268,000	6,544,000	2,870,000
Warrants amended	'	'	'	-6,415,000
Fair value of warrants exercised	'	-420,000	-55,000	'
Reclassification to equity in IPO	-7,200,000	-7,170,000	'	'
Warrant restructuring	'	'	2,485,000	'
Change in fair value of warrants	'	-4,633,000	-7,538,000	10,388,000
Ending balance	'	594,000	12,549,000	11,113,000
Debt Guarantee [Member]	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'
Beginning balance	'	5,679,000	6,993,000	3,793,000
Fair value of warrants issued	'	'	1,583,000	831,000
Warrants amended	'	'	'	-6,415,000
Fair value of warrants exercised	'	'	'	'
Reclassification to equity in IPO	'	-2,514,000	'	'
Warrant restructuring	'	'	268,000	'
Change in fair value of warrants	'	-3,101,000	-3,165,000	8,784,000
Ending balance	'	64,000	5,679,000	6,993,000
Consulting [Member]	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'
Beginning balance	'	147,000	447,000	100,000
Fair value of warrants issued	'	'	'	69,000
Warrants amended	'	'	'	'
Fair value of warrants exercised	'	'	'	'
Reclassification to equity in IPO	'	-108,000	'	'
Warrant restructuring	'	'	'	'
Change in fair value of warrants	'	-38,000	-300,000	278,000
Ending balance	'	1,000	147,000	447,000
Financing [Member]	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'
Beginning balance	'	6,493,000	2,293,000	'
Fair value of warrants issued	'	268,000	4,961,000	1,970,000
Warrants amended	'	'	'	'
Fair value of warrants exercised	'	'	'	'
Reclassification to equity in IPO	'	-4,548,000	'	'
Warrant restructuring	'	'	2,217,000	'
Change in fair value of warrants	'	-1,801,000	-2,978,000	323,000
Ending balance	'	412,000	6,493,000	2,293,000
Series A Preferred Stock [Member]	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'
Beginning balance	'	'	220,000	63,000
Fair value of warrants issued	'	'	'	'
Warrants amended	'	'	'	'
Fair value of warrants exercised	'	'	-55,000	'
Reclassification to equity in IPO	'	'	'	'
Warrant restructuring	'	'	'	'
Change in fair value of warrants	'	'	-165,000	157,000
Ending balance	'	'	'	220,000
Series B Preferred Stock [Member]	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'
Beginning balance	'	230,000	1,160,000	314,000
Fair value of warrants issued	'	'	'	'
Warrants amended	'	'	'	'
Fair value of warrants exercised	'	-420,000	'	'
Reclassification to equity in IPO	'	'	'	'
Warrant restructuring	'	'	'	'
Change in fair value of warrants	'	307,000	-930,000	846,000
Ending balance	'	$117,000	$230,000	$1,160,000

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Financial Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	$594,000	$12,549,000
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	'	'
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	'	'
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	$594,000	$12,549,000

Contingencies_Additional_Infor

Contingencies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Commitments And Contingencies Disclosure [Abstract]	'	'	'
Payment for litigation settlement	$1,000,000	'	'
Amount received from insurance carrier	'	400,000	'
Net recovery (expense) from litigation	'	$200,000	($800,000)

Joint_Venture_Agreement_Additi

Joint Venture Agreement - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended
	Oct. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Oct. 28, 2013	Apr. 10, 2013	Dec. 31, 2012
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'
Capital contribution in exchange of membership interests	'	'	$1,000,000	'	'	'
Common stock, shares issued	10,000	9,275,384	9,275,384	3,286,700	690,000	1,349,936
Additional expense related to shares issued	175,000	231,000	'	'	'	'
Joint Venture Agreement [Member]	'	'	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'
Entered into agreement date	'	'	30-Nov-11	'	'	'
Percentage of outstanding membership interests in joint venture	'	50.00%	50.00%	'	'	'
Capital contribution in exchange of membership interests	1,000,000	'	'	'	'	'
Fair value of capital contribution in joint venture	'	6,000,000	6,000,000	'	'	'
Joint Venture Agreement [Member] | Second Quarter of 2014 [Member]	'	'	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'
Capital contribution in exchange of membership interests	'	'	1,000,000	'	'	'
Joint Venture Agreement [Member] | First Anniversary of Closing Date [Member]	'	'	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'
Capital contribution in exchange of membership interests	'	'	2,000,000	'	'	'
Joint Venture Agreement [Member] | Second Anniversary of Closing Date [Member]	'	'	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'
Capital contribution in exchange of membership interests	'	'	2,000,000	'	'	'
Joint Venture Agreement [Member] | Maximum [Member]	'	'	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'
Capital contribution in exchange of membership interests	'	'	$5,000,000	'	'	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Oct. 10, 2013

Oct. 08, 2013

Sep. 30, 2013

Jul. 06, 2013

Apr. 10, 2013

Aug. 14, 2012

Feb. 29, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2013

Oct. 28, 2013

Sep. 30, 2011

Sep. 15, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Mar. 31, 2011

Dec. 31, 2013

Apr. 10, 2013

Dec. 31, 2013

Oct. 22, 2012

Dec. 31, 2013

Dec. 31, 2013

Apr. 10, 2013

Feb. 29, 2012

Dec. 31, 2013

Dec. 31, 2013

Apr. 10, 2013

Dec. 31, 2013

Dec. 31, 2011

Feb. 29, 2012

Aug. 15, 2010

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 15, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Aug. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Extension

Consulting and Advisory Agreement [Member]

Consulting and Advisory Agreement [Member]

Consulting and Advisory Agreement [Member]

Consulting and Advisory Agreement [Member]

Financial Guarantee [Member]

Mr. Thompson, Chairman Audit Committee [Member]

Mr. Thompson, Chairman Audit Committee [Member]

IPO [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

NNJCA [Member]

NNJCA [Member]

NNJCA [Member]

NNJCA [Member]

NNJCA [Member]

Edmund Cannon [Member]

Edmund Cannon [Member]

Dr. Pecora [Member]

Dr. Pecora [Member]

Dr. Pecora [Member]

Dr. Pecora [Member]

Dr. Pecora [Member]

Dr. Pecora [Member]

Dr. Pecora [Member]

Pecora and NNJCA [Member]

Dr. Chaganti [Member]

Dr. Chaganti [Member]

Dr. Chaganti [Member]

Dr. Chaganti [Member]

Equity Dynamics, Inc. [Member]

Equity Dynamics, Inc. [Member]

Equity Dynamics, Inc. [Member]

Financial Guarantee [Member]

IPO [Member]

Financial Guarantee [Member]

IPO [Member]

Paid in Cash [Member]

Expensed under Stock Option Plan [Member]

Expensed under Stock Option Plan [Member]

Expensed under Stock Option Plan [Member]

2011 Equity Plan [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of revolving line of credit extensions facility

'

'

'

'

'

'

'

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

284,000

'

'

'

202,630

'

1,051,506

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock exercised

'

'

'

'

'

'

'

117,902

54,910

3,546

'

'

'

'

'

'

'

395,825

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants adjusted in conjunction with IPO

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

436,079

'

585,645

'

'

'

'

44,288

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15

'

$15

'

'

'

'

$4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional amount of loan received

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6,750,000

'

'

'

'

$1,500,000

'

'

'

'

'

$500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible shares issued to common stock

'

'

'

'

690,000

'

'

9,275,384

1,349,936

'

10,000

3,286,700

'

'

'

'

'

'

'

'

690,000

'

'

'

675,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion price of notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

'

'

'

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt outstanding under credit agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of outstanding indebtedness to common stock

'

'

'

'

9,634,300

'

'

9,634,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares

'

'

'

'

963,430

'

'

12,596,066

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument spread on variable rate

'

'

'

'

'

'

'

6.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate at period end

'

'

'

'

'

'

'

9.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-payment penalty paid

'

'

'

'

'

'

'

130,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument amount paid upon conversion of the notes

'

'

'

'

'

'

'

32,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes issued to related party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

Interest rate due to related party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.50%

'

'

'

'

'

'

Interest expenses on notes issued to related party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,400

8,400

8,400

'

'

'

'

Stock options issued to purchase shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, vesting period

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consulting and advisory agreement expenses under stock option plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

76,220

430,600

401,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consulting agreement period

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Agreement with related party, fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

'

'

'

'

'

5,000

'

'

'

10,000

'

'

Agreement with related party, consulting fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

'

45,000

0

142,740

235,560

'

60,000

60,000

60,000

'

'

120,000

120,000

Stock option issued to related party

60,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,000

'

'

'

'

'

60,000

'

'

'

'

'

'

Stock option issued to related party, price per share

'

'

'

'

'

'

'

$14.57

$33.80

$26.73

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25

'

'

'

'

'

$25

'

'

'

'

'

'

Common stock, shares purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

Common stock, shares purchased price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15.89

'

'

'

Agreement with related party, one-time payment required

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

Agreement with related party, percentage of net revenues required to be paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

Accrued patents issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

Agreement with related party, description of required payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'In exchange for this assignment, if the USPTO issues a patent for an invention on which Dr. Chaganti is listed as an inventor, we are required to pay Dr. Chaganti (i) a one-time payment of $50,000 and (ii) 1% of any net revenues we receive from any licensed sales of the invention.

'

'

'

'

'

'

Agreement with related party, fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Due to related party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

132,679

Warrants issued

'

'

'

'

'

4,706

28,235

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants at the date of issue

'

'

'

'

'

'

'

144,000

'

'

'

'

6,415,000

'

'

'

'

'

'

69,000

'

'

298,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants agreed to be surrendered

'

23,188

14,313

2,072

'

'

'

'

193,176

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

37,646

'

'

'

'

'

'

'

Increase the pre-payment penalties

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$130,000

'

'

'

'

'

'

'